CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL
Care that inspires

CMMH/BSE/2022-23/40

August 22, 2022

The Bombay Stock Exchange Ltd
PJ Towers, 25th Floor,
Dalal Street, Fort,
Mumbai-400 001.

Script code 523489

Dear Sirs,

Sub: Submission of Notice of 32nd Annual General Meeting and Annual Report for the financial year 2021-22 under regulation 34 of SEBI(LODR) Regulations, 2015.

***

Pursuance to Regulation 34 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed the Notice of 32nd Annual General Meeting and Annual Report for the financial year 2021-22.

Kindly take the above on record.

Thanking you,
Yours faithfully,
For CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LIMITED,

R. DEENADAYALU
COMPANY SECRETARY & COMPLIANCE OFFICER
MEMBERSHIP NO: F3850/MOBILE NO.9283112100

CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LTD. Regd Office 149, Luz Church Road, Mylapore, Chennai 600 004

Encl: As above

32nd Annual Report
2021 - 2022

CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL

Care that inspires

CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LTD.

(Formerly known as Devaki Hospital Limited)

New No. 70, Old No.149, Luz Church Road, Mylapore, Chennai - 600 004.

Ph : 044 - 42938938 Fax : 044 - 24993282

E-mail: cmmhospitals@gmail.com Website: www.cmmh.in

CIN: L85110TN1990PLC019545

GSTIN: 33AAACD2694N1ZF

CORPORATE INFORMATION

BOARD OF DIRECTORS:

Mrs. R. GOMATHI (DIN:02900460) - Managing Director

Mr. A.N. RADHAKRISHNAN (DIN:01508867) - Director

Mr. K. MEYYANATHAN (DIN:07845698) - Independent Director

Mr. N. RAJKUMAR (DIN:00617000) - Independent Director

AUDIT COMMITTEE:

Mr. K. MEYYANATHAN - Chairman
Mr. N. RAJKUMAR - Member
Mrs.R. GOMATHI - Member

DR. V. KRISHNAMURTHY - Chief Executive Officer

MR. DAMBARU DHAR JENA - Chief Financial Officer

COMPANY SECRETARY & COMPLIANCE OFFICER:

Mr. R. DEENADAYALU

REGISTERED OFFICE:

CIN : L85110TN1990PLC019545
New No: 70, Old No: 149, Luz Church Road,
Mylapore, Chennai – 600 004
Ph: 044 – 42938938 Fax : 044-24993282
Email : cmmhospitals@gmail.com
Website: www.cmmh.in

STATUTORY AUDITORS:

M/S. MRC & ASSOCIATES,
Chartered Accountants,(FRN:004005S)
No.7, East Park Road,
Shenoy Nagar, Chennai- 600 030.
Email: gali.chiranjeevi@gmail.com
Ph. No. 044 - 2664 3410 / 2664 2853

SECRETARIAL AUDITORS:

Mr.T. Murugan,
Company Secretaries in Practice,
No.M22E, Sri Subah Colony, Munusamy Road,
K.K.Nagar, Chennai - 600078
Ph. No. 044 - 2366 1875 / Mobile: 93810 35900
Email: murugantmp@yahoo.co.in

BANKERS:

Indian Bank
Punjab National Bank
HDFC Bank

REGISTRARS AND SHARE TRANSFER AGENTS:

M/S. CAMEO CORPORATE SERVICES LIMITED,
"Subramanian Building", No.1,
Club House Road, Chennai - 600002
Ph: 044-28460390 (5 Lines)
Email : investor@cameoindia.com
Website : www.cameoindia.com

LISTING:

The Bombay Stock Exchange Limited

DATE AND TIME OF MEETING:

Wednesday, 14th September, 2022, 14.00 Hours

CONTENTS

	Page No.
01. Notice of Annual General Meeting	4
02. Directors' Report	14
03. Management Discussion and Analysis Report	30
04. Secretarial Audit Report	35
05. Conservation of Energy, Research Development, Technology Absorption, Foreign Exchange Earnings and Outgo	41
06. Independent Auditors' Report	44
07. Balance Sheet	58
08. Statement of Profit and Loss	59
09. Statement of Cash Flow	61
10. Notes forming part of financial statements	62

VISION

To be the premier medical centre distinguished by its passion in providing excellent affordable holistic healthcare to all.

MISSION

To bring affordable quality healthcare.

To Provide efficient, effective timely care with human touch to our patients.

To achieve excellence in healthcare management through sincerity, competency building and compassion in alleviating, suffering and restoring health.

NOTICE OF ANNUAL GENERAL MEETING

NOTICE is hereby given that the 32nd Annual General Meeting of the members of CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LIMITED will be held on Wednesday, 14th September, 2022 at 14.00 IST through Video Conference (VC) or Other Audio Visual Means (OAVM) to transact the following:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Balance Sheet as on 31st March, 2022 and the statement of Profit & Loss for the year ended on that date and the report of the Directors and Auditors thereon.
2. To appoint a director in the place of Mr. A.N. Radhakrishnan (DIN:01508867) who retires by rotation and being eligible, offers himself for re-appointment.
3. To consider and if thought fit, to pass with or without modification(s) the following resolution as an ORDINARY RESOLUTION:

To re-appoint M/S. MRC & Associates, Chartered Accountants as Statutory Auditors of the Company and to authorize the Board of Directors of the Company to fix their remuneration:

"RESOLVED THAT pursuant to Section 139 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 as amended from time to time ("Act"), M/S. MRC & Associates, Chartered Accountants, (Firm Registration No.004005S) be re-appointed as Statutory Auditors of the Company for a second term of 5 (five) years to hold office from the conclusion of this 32nd Annual General Meeting until the conclusion of the 37th Annual General Meeting of the Company at such remuneration plus applicable taxes and reimbursement of out-of-pocket expenses in connection with the audit as may be decided by the Board of Directors of the Company."

BY ORDER OF THE BOARD
For CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LIMITED

R. DEENADAYALU
COMPANY SECRETARY & COMPLIANCE OFFICER
M.No.F3850

Registered Office:
Chennai Meenakshi Multispeciality Hospital Limited,
New No.70, Old No.149, Luz Church Road, Chennai - 600 004.
CIN: L85110TN1990PLC019545 Ph : 044-42938938 ; Fax : 044 - 24993282
E-mail: cmmhospitals@gmail.com; Website: www.cmmh.in

Place : Chennai
Date : 13th August, 2022

NOTE:

- In view of the situation arising due to COVID-19 global pandemic, the Annual General Meeting of the companies shall be conducted as per the guidelines issued by the Ministry of Corporate Affairs (MCA)vide Circular No.14/2020 dated April 8,2020, Circular No.17/2020 dated April 13,2020, Circular No. 20/2020 dated May 05, 2020 and Circular No.02/2021 dated January 13, 2021 and General Circular No.21/2021, dated 14.12.2021. The forthcoming AGM will thus be held through video conferencing (VC) or other audio visual means (OAVM). Hence, Members can attend and participate in the ensuing AGM through VC/OAVM.
- Additional information pursuant to Regulation 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of the reappointment of Director as mentioned under item no.2 of this notice is appended. Further, the Company has received relevant disclosure/consent from the Director seeking appointment.
- The Register of Members and Share Transfer Books of the Company will remain closed from 08th September, 2022 to 14th September, 2022 (both days inclusive) in terms of the provisions of Section 91 of the Companies Act, 2013 and the applicable clauses of the SEBI (Listing Obligations and Disclosures Requirements Regulations) 2015.
- In compliance with the aforesaid MCA Circulars and SEBI Circular dated May 13, 2022 Notice of the AGM along with the Annual Report 2021-22 is being sent only through electronic mode to those Members whose email addresses are registered with the Company/ Depositories. Members may note that the Notice and Annual Report 2021-22 will also be available on the Company's website www.cmmh.in, websites of the Stock Exchange i.e. BSE Limited at www.bseindia.com.
- The Securities and Exchange Board of India has mandated submission of Permanent Account Number(PAN) by every participant in securities market. Members holding shares in demat form are, therefore, requested to submit PAN details to the Depository Participants with whom they have demat accounts. Members holding shares in physical form can submit their PAN details to M/s. Cameo Corporate Services Limited, the Registrar & Share Transfer Agent of the Company.
- As per Regulation 40 of SEBI Listing Regulations, as amended, securities of listed companies can be transferred only in dematerialized form with effect from April 1, 2019, except in case of request received for transmission or transposition of securities. In view of these members holding shares in physical form are requested to consider converting their holdings to dematerialized form. Members can contact the Company or Company's Registrars and Transfer Agents, Cameo Corporate Services Limited for assistance in this regard.
- Since the AGM will be held through VC/OAVM, the Route Map is not annexed in this Notice.

CDSL e-Voting System – For Remote e-voting

THE INTRUCTIONS OF SHAREHOLDERS FOR REMOTE E-VOTING:

Step 1 : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

Step 2 : Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

(i) The voting period begins at 9.00 am on Sunday, 11th September, 2022 and ends at 5.00 pm on Tuesday, 13th September, 2022. During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date Wednesday, 7th September, 2022 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.

(ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.

(iii) Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

Step 1 : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

(iv) In terms of SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to abovesaid SEBI Circular, Login method for e-Voting for Individual shareholders holding securities in Demat mode CDSL/NSDL is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL Depository	1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are https://web.cdslindia.com/myeasi/home/login or visit www.cdslindia.com and click on Login icon and select New System Myeasi. 2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period. Additionally, there is also links provided to access the system of all e-Voting Service Providers i.e. CDSL/NSDL/KARVY/LINKINTIME, so that the user can visit the e-Voting service providers' website directly. 3) If the user is not registered for Easi/Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration 4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page or click on https://evoting.cdslindia.com/Evoting/EvotingLogin. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.

Individual Shareholders holding securities in demat mode with NSDL Depository	1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period.
	2) If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS "Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp
	3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period.

Individual Shareholders (holding securities in demat mode) login through their Depository Participants (DP)	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33
Individual Shareholders holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30

Step 2 : Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

v) Login method for Remote e-Voting for Physical shareholders and shareholders other than individual holding in Demat form.

1) The shareholders should log on to the e-voting website www.evotingindia.com.

2) Click on "Shareholders" module.

3) Now enter your User ID

a. For CDSL: 16 digits beneficiary ID,

b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,

c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.

4) Next enter the Image Verification as displayed and Click on Login.

5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.

6) If you are a first-time user follow the steps given below:

	For Physical shareholders and other than individual shareholders holding shares in Demat.
PAN	Enter your 10 digit alpha-numeric PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) Shareholders who have not updated their PAN with the Depository Participant are requested to use the sequence number sent by RTA or contact RTA.
Dividend BankDetails OR Date ofBirth (DOB)	Enter the Dividend Bank Details or Date of Birth in (dd/mm/yyyy) format as recorded in your demat account or in the company records in order to login. If both the details are not recorded with the depository, please enter the member id / folio number in the Dividend Bank details field.

vi. After entering these details appropriately, click on "SUBMIT" tab.

vii. Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. Itis strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

viii. For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.

ix. Click on the EVSN for the relevant Chennai Meenakshi Multispeciality Hospital Limited on which you choose to vote.

x. On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.

xi. Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.

xii. After selecting the resolution, you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.

xiii. Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.

xiv. You can also take a print of the votes cast by clicking on "Click here to print" option on the Voting page.

xv. If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.

xvi. Additional Facility for Non – Individual Shareholders and Custodians –For Remote Voting only.

- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the "Corporates" module.
- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
- After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
- A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.

Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address cmmhcosec@gmail.com, if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES FOR OBTAINING LOGIN CREDENTIALS FOR e-VOTING FOR THE RESOLUTIONS PROPOSED IN THE NOTICE:

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to RTA email id.: investor@cameoindia.com

2. For Demat shareholders - Please update your email id & mobile no. with your respective Depository Participant (DP)

3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call at toll free no. 1800 22 55 33

The Company has appointed Mr. T. Murugan, Practicing Company Secretary, to act as the Scrutinizer, for conducting the scrutiny of the votes cast and he has communicated his willingness to be appointed.

The Scrutinizer, after scrutinizing the votes cast during the AGM and through remote e-voting, will not later than three days of conclusion of the Meeting, make a consolidated scrutinizer's report and submit the same to the Chairman. The results declared along with the consolidated scrutinizer's report shall be placed on the website of the Company www.cmmh.in and CDSL website. The results shall simultaneously be communicated to the Bombay Stock Exchange Limited.

BY ORDER OF THE BOARD
For CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LIMITED

R. DEENADAYALU
COMPANY SECRETARY & COMPLIANCE OFFICER
M.No.F3850

Registered Office:
Chennai Meenakshi Multispeciality Hospital Limited,
New No.70, Old No.149, Luz Church Road, Chennai - 600 004.
CIN: L85110TN1990PLC019545 Ph : 044-42938938 ; Fax : 044 - 24993282
E-mail: cmmhospitals@gmail.com; Website: www.cmmh.in

Place : Chennai
Date : 13th August, 2022

ANNEXURE TO THE NOTICE AS PER REGULATION 36(3) OF SEBI LODR 2015 AND AS PER SECRETARIAL STANDARDS ON GENERAL MEETING ADDITIONAL INFORMATION ABOUT THE DIRECTOR PROPOSED TO BE RE-APPOINTED.

Name of Director - Mr. A.N. Radhakrishnan : (DIN:01508867)

Date of Birth / Age: 24th May, 1940 – Age 82 years

Qualification: N. DCom.

Experience 57 years

Terms and Conditions of Appointment/Re-appointment: Retirement by rotation and Re-appointment.

Date of First Appointment : 29th April, 2007

Expertise in specific General Functional area: General Office Management and Administration

Shareholding in the Company: 3757166 (50.30%) Equity Shares of ` 10/- each.

Relationship with other directors and KMP: Mr. A.N. Radhakrishnan is the husband of Mrs. R. Gomathi, Managing Director.

No. of Board meetings attended during the Financial Year 2021-22: 7

List of outside Directorships held :1. RMG Benefit Fund Limited (CIN:U65991TN1995PLC033583)
2. Meenakshi Networks Pvt. Ltd (CIN: U92490TN2011PTC083667)

Chairman/Member of the Committee of the Board of Directors of the Company : Member in the Nomination and Remuneration Committee, Stakeholders Relationship Committee, Internal Complaints Committee.

Chairman/Member of the Committee of Directors of other Public Limited Companies in which he is a Director : Nil

Details of Remuneration to be approved : Nil

Last approved remuneration drawn : Not applicable

None of the Directors or Key Managerial Personnel of the Company or their relatives except Mrs. R. Gomathi (DIN: 02900460), Managing Director who is holding 408892 (5.47%) equity shares of ` 10/- each in the Company and Mr. A.N. Radhakrishnan (DIN No.01508867), Director being the appointee is deemed to be interested or concerned in the resolution.

Accordingly the Board recommends the resolution for approval by the Shareholders of the Company as an ORDINARY RESOLUTION as set forth in Item No.2 of the Notice.

DIRECTORS' REPORT

To the Members of Chennai Meenakshi Multispeciality Hospital Limited.

Your Directors present their 32nd Annual Report together with the Audited Statement of Accounts of the Company for the financial year ended 31st March 2022.

FINANCIAL RESULTS: **(₹ in Lakhs)**

Particulars	Year ended 31st March, 2022	Year ended 31st March, 2021
Gross Income	3177.53	2000.09
Profit / (Loss) Before Depreciation, Tax & Financial Expenses	613.40	115.64
Interest	98.49	113.90
Depreciation	117.32	126.72
Profit / (Loss) Before Tax	397.59	(124.98)
Less: Exceptional Items	-	-
Tax Expenses:		
a. Current Tax	-	-
b. Fringe Benefit Tax	-	-
c. Deferred Tax Liability	-	-
Other Comprehensive Income		
(i) Items that will not be reclassified to profit or Loss		
(a) Re measurement of net defined benefit Liability / Asset	1.76	4.01
Profit/ (Loss) for the year carried to Balance Sheet	399.35	(120.97)

OPERATIONS AND FINANCIAL PERFORMANCE:

The revenue of the Company for the Financial Year 2021-2022 is ₹ 3177.53 Lakhs compared to the total revenue of ₹ 2000.09 Lakhs in the previous year. The profit for the Financial Year 2021-2022 is ₹ 397.59 Lakhs as against a loss of ₹ (124.98) Lakhs in the previous year (excluding Other Comprehensive Income). The profit of the Company for the Financial Year 2021-2022 is ₹ 399.35 lakhs as against the loss After Tax of ₹ (120.97) Lakhs in the previous year. The other comprehensive income for the Financial Year 2021-2022 is ₹ 1.76 Lakhs as against ₹ 4.01 Lakhs in the previous year. The detailed over view of the Company performance during the financial year 2021-22 is given in Annexure-I to the Directors Report - Management Discussion and Analysis Report. On approval by the Government of Tamilnadu to admit COVID 19 patients also your hospital has seen improvement during the months of May, 2021 and June, 2021 and again returned to normal performance subsequently.

DIRECTORS & KEY MANAGERIAL PERSONNEL:

In accordance with Section 152 of the Companies Act, 2013 Mr. A.N. Radhakrishnan, (DIN:01508867) will retire by rotation at this ensuing Annual General Meeting. He being eligible, offers himself for re-appointment. The subject forms part of the ordinary business in the Notice of the 32nd Annual General Meeting.

Mr.N. Rajkumar (DIN:00617000) resigned with effect from 20.05.2021 and again appointed as Additional Director (Independent) for five years with effect from 09.06.2021 for 5 (five years) and regularized as Independent Director in the Annual General Meeting held on 15.09.2021. Mr. B. Ramachandran (DIN: 06397113), Independent Director resigned with effect from 09.06.2021. Mr. K. Meyyanathan (DIN: 07845698) was appointed as an Additional Director (Independent) for five years with effect May 20, 2021 and regularized as Independent Director in the Annual General Meeting held on 15.09.2021

DIVIDEND:

Though there is Profit in the year 2021-22 the Board of Directors has not recommended any dividend for the financial year ended 31st March 2022 due to pending of accumulated losses.

UNPAID / UNCLAIMED DIVIDEND:

In compliance with the provisions of Section 124 of the Companies Act, 2013 and rules made thereunder the Company had no unclaimed dividend to be transferred to Investor Education and Protection Fund and there is no unclaimed dividends lying in the Company's Unpaid Dividend Account.

TRANSFER TO RESERVES IN TERMS OF SECTION 134 (3) (J) OF THE COMPANIES ACT, 2013:

For the financial year ended 31st March 2022, the Company has not proposed to carry any amount to General Reserve Account due to pending of accumulated losses.

COMMISSION RECEIVED BY DIRECTOR FROM HOLDING OR SUBSIDIARY COMPANY:

The Company neither has any holding nor is any subsidiary company, therefore, disclosure under Section 197(14) of the Companies Act, 2013 is not applicable.

MATERIAL CHANGES AND COMMITMENTS

There have been no material changes and commitments affecting the financial position of the Company occurred between the end of the financial year to which this financial statements relate and the date of this report.

ANNUAL EVALUATION OF BOARD'S PERFORMANCE:

Pursuant to the provisions of the Companies Act, 2013 and SEBI Guidance note on Board evaluation issued by SEBI vide its circular dated January 5, 2017, the annual performance evaluation of its Board, the directors individually and Committees of the board viz., Audit and Nomination and Remuneration Committee has been carried out.

The board and the committee were evaluated on various criteria as stated below:

1. Composition of the Board and Committee.
2. Understanding of the Company and its business by the Board.
3. Availability of information to the board and committee.
4. Effective Conduct of Board and Committee Meetings.
5. Monitoring by the Board management effectiveness in implementing strategies, managing risks and achieving the goals.

The Board also carried out the evaluation of directors and chairman based on following criteria:

1. Attendance at the meetings.
2. Understanding and knowledge of the entity.
3. Maintaining Confidentiality of board discussion.
4. Contribution to the board by active participation.
5. Maintaining independent judgment in the decisions of the Board

SUCCESSION PLANNING:

The Nomination and Remuneration Committee works with the Board on the succession plan and prepares for the succession in case of any exigencies.

NUMBER OF MEETINGS OF BOARD AND AUDIT COMMITTEE:

The Board meets at regular intervals to discuss and decide on business strategies / policies and review the financial performances of the Company. The Board Meetings are pre-scheduled and a tentative annual calendar of the Board is circulated to the Directors well in advance to facilitate the Directors to plan their schedules. The details of number of board meetings and other committee meetings held during the Financial Year 2021-22 are as follows:

BOARD MEETINGS

Name	Date of Meeting 20.05.2021	Date of Meeting 09.06.2021	Date of Meeting 28.06.2021	Date of Meeting 13.08.2021	Date of Meeting 11.11.2021	Date of Meeting 13.12.2021	Date of Meeting 12.02.2022
R. Gomathi	Attended	Attended	Attended	Attended	Attended	Attended	Attended
A.N. Radhakrishnan	Attended	Attended	Attended	Attended	Attended	Attended	Attended
B. Ramachandran	Attended	Attended & Resigned after the meeting	-	-	-	-	-
K. Meyyanathan	Joined on 20-05-2021	Attended	Attended	Attended	Attended	Attended	Attended
N. Rajkumar	Attended & Resigned after the meeting	Joined on 09-06-2021	Attended	Attended	Attended	Attended	Attended

AUDIT COMMITTEE MEETINGS

Name	Date of Meeting 20.05.2021	Date of Meeting 09.06.2021	Date of Meeting 28.06.2021	Date of Meeting 13.08.2021	Date of Meeting 11.11.2021	Date of Meeting 13.12.2021	Date of Meeting 12.02.2022
B. Ramachandran	Attended	Attended & Resigned after the meeting	-	-	-	-	-
K. Meyyanathan	Joined on 20-05-2021	Attended	Attended	Attended	Attended	Attended	Attended
R. Gomathi	Attended	Attended	Attended	Attended	Attended	Attended	Attended
N.Rajkumar	Attended & Resigned after the meeting	Joined on 09-06-2021	Attended	Attended	Attended	Attended	Attended

NOMINATION AND REMUNERATION COMMITTEE MEETINGS

Name	Date of Meeting 20.05.2021	Date of Meeting 09.06.2021	Date of Meeting 28.06.2021	Date of Meeting 13.08.2021	Date of Meeting 11.11.2021	Date of Meeting 13.12.2021
B. Ramachandran	Attended	Attended & Resigned after the meeting	-	-	-	-
N. Rajkumar	Attended & Resigned after the meeting	Joined on 09-06-2021	Attended	Attended	Attended	Attended
A.N. Radhakrishnan	Attended	Attended	Attended	Attended	Attended	Attended
K. Meyyanathan	Joined on 20-05-2021	Attended	Attended	Attended	Attended	Attended

STAKEHOLDERS RELATIONSHIP COMMITTEE MEETING

Name	Date of Meeting 30.04.2021	Date of Meeting 11.10.2021	Date of Meeting 18.10.2021	Date of Meeting 11.02.2022	Date of Meeting 30.03.2022
B. Ramachandran (Resigned at the conclusion of board meeting held on 09-06-2021)	Attended	-	-	-	-
K. Meyyanathan (Joined on 20-05-2021)	-	Attended	Attended	Attended	Attended
A.N. Radhakrishnan	Attended	Attended	Attended	Attended	Attended
N. Rajkumar	Attended	Attended	Attended	Attended	Attended

COMPOSITION OF BOARD:

The Board consists of the following:

Mrs. R. GOMATHI (DIN: 02900460) - Managing Director

Mr. A.N. RADHAKRISHNAN (DIN: 01508867) – Non Executive Director

Mr. B. RAMACHANDRAN (DIN: 06397113) - Independent Director (Till 9th June, 2021)

Mr. K. MEYYANATHAN (DIN: 07845698) - Independent Director (from May 20, 2021.

Mr. N. RAJKUMAR(DIN:00617000) - Independent Director (from 9th February, 2021 to 20th May, 2021 and from 9th June, 2021 and continuing)

1. No. of Board Meetings: 7: 20th May, 2021; 09th June, 2021; 28th June, 2021; 13th August 2021; 11th November, 2021; 13th December, 2021 and 12th February, 2022.

The interval between two Board Meetings was well within the maximum period mentioned under section 173 of the Companies Act, 2013, and SEBI Listing (Disclosures and Obligations Requirements) Regulations, 2015.

COMPOSITION OF COMMITTEES OF BOARD:

Currently the board has following Committees: Audit Committee, Nomination & Remuneration Committee, Stakeholders Relationship Committee, Internal Complaints Committee, Whistle Blower Committee and Independent Directors Committee.

The Composition & Activities are as follows:

Name of the Committee	Composition of the Committee/ No of times the committee met	Highlights of duties, responsibilities & Activities
Audit Committee	Mr. B. Ramachandran- DIN: 06397113 (Independent Director), Chairman of the Committee (Till 9th June 2021) Mrs. R. Gomathi - DIN:02900460 Managing Director-Member Mr. N. Rajkumar - DIN:00617000 (Independent Director) - Member till 20th May, 2021 & from 9th June, 2021 Mr. K. Meyyanathan (DIN:07845698) - (Independent Director-Chairman from (from June 28, 2021) Mr. R. Deenadayalu Secretary of the Committee (Company Secretary) The Committee met 7 times on 20th May 2021, 9th June 2021; 28th June 2021, 13th August, 2021; 11th November, 2021; 13th December, 2021 and 12th February, 2022	⇨ The Audit Committee was mandated with the same Terms of Reference specified in SEBI (LODR) REGULATIONS, 2015. ⇨ The current Terms of Reference fully conform to the requirements of the Companies Act. ⇨ The Audit committee is responsible for overseeing the Company's financial reporting process, reviewing the quarterly/half-yearly/annual financial statements, reviewing with the management the financial statements and adequacy of internal audit function, recommending the appointment/re-appointment of statutory auditors and fixation of audit fees, reviewing the significant internal audit findings/related party transactions, reviewing the Management Discussion and Analysis of financial condition and result of operations and also statutory compliance issues. ⇨ The Committee acts as a link between the management, external and internal auditors and the Board of Directors of the Company.

Nomination & Remuneration Committee	Mr. B. Ramachandran DIN No: 06397113 (Independent Director), Member of the Committee till 9th June, 2021 Mr. A.N. Radhakrishnan- DIN: 01508867 (Non-Executive Director), Member of the Committee Mr. N. Rajkumar- DIN:00617090 (Independent Director), Chairman of the Committee Mr. K. Meyyanathan DIN:07845698-(Independent Director), Member of the Committee from 20th May 2021. The Committee met six times on 20th May, 2021; 09th June, 2021; 28th June, 2021; 13th August 2021; 11th November, 2021 & 13th December 2021.	⇨ To fix salary allowances and other perks to senior level personnel as and when appointed by the Company. *REMUNERATION POLICY*: The Remuneration Policy of the Company for the managerial personnel is based on the performance potential and performance of the individual/personnel. CEO/CFO CERTIFICATION by Dr. V. Krishnamurthy, Chief Executive Officer and Mrs. R. Gomathi, Managing Director as required under SEBI (LODR) was placed before the Board at its meeting held on 30th May, 2022.

Stakeholders Relationship Committee	Mr. B. Ramachandran - DIN: 06397113 (Independent Director), Chairperson of the Committee till 9th June 2021, Mr. A.N. Radhakrishnan- DIN: 01508867 (Non-Executive Director), Member of the Committee Mr. N. Rajkumar- DIN:00617000 (Independent Director), Member of the Committee from 9th February, 2021 to 20th May, 2021 and from 9th June, 2021-Member Mr. K. Meyyanathan - DIN:07845698 (Independent Director), Chairman of the Committee from 9th June, 2021. The Committee met five time on 30th April, 2021; 11th October, 2021; 18th October, 2021; 11th February, 2022 & 30th March, 2022	⇨ The Company has attended to the investors' complaints and redressed them within 15 days from the date of their receipt during the year 2021-2022. The Committee also approved share transfers / transmission/issue of duplicate shares, etc.

DECLARATION OF INDEPENDENCE:

All independent Directors have given declarations that they meet the criteria of independence as laid down under Section 149 of the Companies Act, 2013 which has been relied on by the Company and placed at the Board Meeting of the Company.

NOMINATION AND REMUNERATION POLICY:

Pursuant to Section 178(3) of the Companies Act, 2013, the Board of Directors has framed a policy which lays down a framework in relation to remuneration of Directors, Key Managerial Personnel and Senior Management of the company. The policy also lays down the criteria for selection and appointment of Board Members. The Remuneration Policy is available on the website of the company. The salient features of the policy are given below:

Nomination & remuneration policy:

In accordance with the Nomination and Remuneration Policy, the Nomination and Remuneration Committee has, inter alia, the following responsibilities:

1.The Committee shall formulate the criteria for determining qualifications, positive attributes and independence of a director.

2.The Committee shall identify persons who are qualified to become Director and persons who may be appointed in Key Managerial and Senior Management positions in accordance with the criteria laid down in this policy.

3.Recommend to the Board, appointment and removal of Director, KMP and Senior Management Personnel.

4.The Board shall carry out evaluation of performance of every Director, Managerial Person, KMP and Senior Management Personnel at regular interval (yearly).

5.The remuneration/ compensation/ commission etc. to the Managerial Person, KMP and Senior Management Personnel will be determined by the Committee and recommended to the Board for approval. The remuneration/ compensation/ commission etc. shall be subject to the prior/ post approval of the shareholders of the Company and Central Government, wherever required.

6.Increments to the existing remuneration/ compensation structure may be recommended by the Committee to the Board which should be within the slabs approved by the Shareholders in the case of Managerial Personnel.

7.Where any insurance is taken by the Company on behalf of its Managerial Personnel, Chief Executive Officer, Chief Financial Officer, the Company Secretary and any other employees for indemnifying them against any liability, the premium paid on such insurance shall not be treated as part of the remuneration payable to any such personnel. Provided that if such person is proved to be guilty, the premium paid on such insurance shall be treated as part of the remuneration.

8.The Non-Executive/ Independent Director may receive remuneration by way of fees for attending meetings of Board or Committee thereof provided that the amount of such fees shall not exceed ` One lakh per meeting of the Board or Committee or such amount as may be prescribed by the Central Government from time to time.

9. Commission to Non-Executive/ Independent Directors may be paid within the monetary limit approved by shareholders, subject to the limit not exceeding 1% of the net profits of the Company computed as per the applicable provisions of the Companies Act, 2013.

RISK MANAGEMENT:

The Company has in place a Risk Management Policy duly approved by the board which is periodically reviewed by the management. The main objective of the company's Risk Management Policy is to ensure the effective identification and reporting of risk exposures, involvement of all departments and employees in risk management, to ensure continuous growth of business and protect all the stakeholders of the Company.

The Audit Committee and Board of Directors consider the risk exposure before approving a strategic decisions taken by the Company. Further the Company has strong internal control system in place to identify the risks at any stage of the business. This internal control system is further reviewed by the internal auditors of the Company and a report is submitted to the Audit Committee. The Committee based on the report of internal auditors advises on the necessary action to be taken in case of any deviation from required standards.

AUDITORS:

M/S. MRC & Associates (FRN.004005S) Chartered Accountants, Chennai-600 030 are the Statutory Auditors of the Company who were appointed at the 27th Annual General Meeting held on 15th September, 2017 to hold office until the conclusion of 32nd Annual General Meeting.

Consequently, M/S. MRC & Associates (FRN.004005S) Chartered Accountants complete their first term of five consecutive years as the statutory auditors of the company at the conclusion of 32nd Annual General Meeting of the company. Pursuant to Section 139(2) of the Act, the company can appoint an auditors firm for consecutive period of five years.

M/S. MRC & Associates (FRN.004005S) Chartered Accountants, have consented to the said reappointment, and confirmed that their reappointment, if made, would be within the limits specified under Section 143(3)(g) of the Act. They have further confirmed that they are not disqualified to be reappointed as statutory auditors in terms of the provisions of the Act, and the provisions of the Companies (Audit and Auditors) Rules, 2014, as amended from time to time.

The Audit Committee and the Board of Directors recommend the reappointment of M/S. MRC & Associates (FRN.004005S) Chartered Accountants as Statutory Auditors of the company from the conclusion of the 32nd AGM till the conclusion of 37th AGM, to the members.

COST AUDIT:

Pursuant to notification of Companies (Cost Records and Audit) Rules, 2014 read with Companies (Cost Records and Audit) amendment rules, 2014, the Company's product does not fall under the purview of Cost Audit.

MANAGEMENT DISCUSSION ANALYSIS REPORT:

The report has been presented separately detailing the overall status of economy, industry and business of the Company in Annexure I.

SECRETARIAL AUDITORS:

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and rules made there under, the Company has appointed Mr. T. Murugan, Practising Company Secretary to undertake the Secretarial Audit of the Company. The Secretarial Audit Report for the year 2021-22 is included as “Annexure II” and forms an integral part of this Report. The Secretarial Audit Report was placed before the Board on 30th May 2022. There are no qualifications in the Secretarial Audit Report.

EXTRACT OF ANNUAL RETURN:

The Annual Return in accordance with Section 92(3) of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014, is available on company's website and can be accessed at www.cmmh.in

RELATED PARTY TRANSACTIONS:
During the financial year 2021-22, your Company has entered into transactions with related parties as defined under Section 2(76) of the Companies Act, 2013 read with Companies (Specification of Definitions Details) Rules, 2014, which were in the ordinary course of business and on arms' length basis and in accordance with the provisions of the Companies Act, 2013, Rules issued there under. There are no materially significant related party transactions made by the Company with Promoters, Directors, Key Managerial Personnel or other designated persons which may have a potential conflict with the interest of the Company at large. Disclosure in Form AOC-2 is attached (ANNEXURE-III).

The details of the related party transactions as required under Indian Accounting Standard – 24 are set out in Note to the standalone financial statements forming part of this Annual Report.

LOANS, GUARANTEES OR INVESTMENTS:
Details of Loans, Guarantees and Investments covered under the provisions of Section 186 of the Companies Act, 2013 are given in the notes to financial statement.

VIGIL MECHANISM:
Your Company has in place Whistle Blower Policy approved by Board of Directors in compliance with provisions of Section 177 (10) of the Companies Act, 2013. The policy provides a mechanism to the Directors and Employees to voice their concerns regarding irregularities in the Company in an effective manner. The mechanism provides for adequate safeguards against victimization of Directors and employees to avail the mechanism and also provides for direct access to the Chairman of the Audit Committee in exceptional cases.

The amended policy pursuant to SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 effective from 1st April, 2019 has been uploaded in the website of the Company at www.cmmh.in.

AUDIT COMMITTEE RECOMMENDATION:
During the year all the recommendations of the Audit Committee were accepted by the Board. Pursuant to Section 177(8) of the Companies Act, 2013, the Composition of Audit Committee is given as under:

Mr. B. Ramachandran-DIN: 06397113 (Independent Director), Chairman of the Committee till 9th June, 2021, Mr. K. Meyyanathan, Independent Director, Chairman from 28th June, 2021, Mrs. R. Gomathi-DIN:02900460, Member; Mr.N.Rajkumar-DIN:00617000, Member till 20th May 2021 and from 9th June, 2021. Company Secretary of the Company is the Secretary of the Committee.

PUBLIC DEPOSITS:
The Company has not accepted any deposits from the public during the period 2021-2022 within the meaning of Sections 73 and 74 of the Companies Act, 2013 read together with the Companies (Acceptance of Deposits)Rules, 2014.

INTERNAL COMPLAINTS COMMITTEE-SEXUAL HARASSMENT AT WORK PLACE:
The Company has in place an Anti Sexual Harassment Policy in line with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. The Internal Complaints Committee ("ICC") has been set up to redress the complaints received regarding sexual harassment. All employees are covered under this policy. No Complaints were received during the year under review. The Policy is also available on our website at the link:www.cmmh.in.

INDEPENDENT DIRECTORS COMMITTEE:
The Company has in place Independent Directors Committee as required under SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015.

CORPORATE GOVERNANCE:
As prescribed under the provisions of Regulation 15(2) of SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015, your Company does not fall under the purview of complying with the provisions of Corporate Governance. During the year your Company has informed the non-applicability provision to the Bombay Stock Exchange. Since, the provision of Corporate Governance is not applicable for the entire Financial Year 2021-22, a separate report of Corporate Governance is not disclosed in the Annual Report 2021-22.

LISTING FEES:
The Company confirms that it has paid the annual listing fees for the year 2022-23 to the Bombay Stock Exchange.

CLOSURE OF REGISTER OF MEMBERS AND SHARE TRANSFER BOOKS:
The Register of Members and Share Transfer books of the company will be closed with effect from 08th September, 2022 to 14th September, 2022 (both days inclusive).

DIRECTORS' RESPONSIBILITY STATEMENT:
Pursuant to Section 134(3)(c) of the Companies Act, 2013, the Directors confirm that:

In the preparation of the annual accounts for the financial year ended 31st March, 2022, the applicable accounting standards and Schedule III of the Companies Act, 2013, have been followed and there are no material departures from the same;

The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of your Company as at 31st March, 2022 and of the statement of profit and loss of the Company for the financial year ended 31st March, 2022;

Proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

The annual accounts have been prepared on a 'going concern' basis;

Proper internal financial controls laid down by the Directors were followed by the Company and that such internal financial controls are adequate and were operating effectively; and Proper systems to ensure compliance with the provisions of all applicable laws were in place and that such systems were adequate and operating effectively.

PERSONNEL:

None of the employees of the Company drew remuneration which in the aggregate exceeded the limits fixed under Section 134(3)(q) read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

RATIO OF REMUNERATION TO EACH DIRECTOR:

The information required pursuant to Section 197 read with Rule 5 of The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 in respect of employees of the Company and Directors is furnished hereunder:

(₹ In lakhs)

S. No	Name	Designation	Remuneration for FY 2021-22	Remuneration for FY 2020-21	Increase in remuneration from previous year	Ratio / times per median of employee remuneration
1	A.N.Radhakrishnan	Chairman & Managing Director(upto 11th November, 2020)	-	5.50	-	4.84:1 (2020-21)
2	R.Gomathi	Managing Director(From 11th November, 2020)	9.00	3.50 (from 11.11.2020)	-	4.55:1
3	Dr.V.Krishnamurthy	Chief Executive Officer	216.00	216.00	-	109.09:1
4	R.Deenadayalu	Company Secretary	17.39	14.90	2.49	9.03:1
5	Dambaru Dhar Jena	Chief Financial Officer	4.86	4.60	0.26	2.48:1
6	K. Meyyanathan	Independent Director	-	-	-	-
7	N. Rajkumar	Independent Director	-	-	-	-

<table>
<tr><td>The percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year:</td><td>Chief Executive Officer : Nil
Company Secretary : 16.71%
Chief Financial Officer : 5.65%</td></tr>
<tr><td>The percentage increase in the median remuneration of employees in the financial year</td><td>13.05%</td></tr>
<tr><td>The number of permanent employees on the rolls of company</td><td>234</td></tr>
<tr><td>The explanation on the relationship between average increase in remuneration and company performance</td><td>The employees on an average received an annual increase of 5.13% based on the performance of the individuals and company.</td></tr>
<tr><td>Comparison of the remuneration of the key Managerial Personnel against the performance of the Company</td><td>The remuneration payable to Key Managerial Personnel is in accordance with Industry, Geographical Standards, qualifications, field experience, experience of the individuals, administrative qualities, contribution made by them and as per the Remuneration Policy of the company.</td></tr>
<tr><td>Variations in the market capitalization of the company, price earnings ratio as at the closing date of the current financial year and previous financial year and percentage increase over decrease in the market quotations of the shares of the company in comparison to the rate at which the company came out with the last public offer in case of listed companies, and in case of unlisted companies, the variations in the net worth of the company as at the close of the current financial year and previous financial year</td><td>
<table>
<tr><th>Particulars</th><th>31.03.2022</th><th>31.03.2021</th><th>change</th></tr>
<tr><td>Stock Price (in ₹)</td><td>23.15</td><td>10.31</td><td>124.54%</td></tr>
<tr><td>Market Cap (₹ In Crores)</td><td>17.29</td><td>7.70</td><td>124.54%</td></tr>
<tr><td>EPS - ₹</td><td>5.32</td><td>(1.67)</td><td></td></tr>
<tr><td>P/E</td><td>4.35</td><td>-</td><td></td></tr>
</table>
</td></tr>
</table>

CONSERVATION OF ENERGY AND TECHNOLOGY ABSORPTION:

The information on conservation of energy, technology absorption as stipulated under Section 134 of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014, is set out herewith as "Annexure[IV]" to this Report.

SIGNIFICANT/MATERIAL ORDERS PASSED BY THE REGULATORS:

During the year, the Company has not received any significant and material orders passed by the Regulators or courts or tribunals which would affect the going concern status of the Company and its future operations.

DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF:

During the year under review there was no instance of one-time settlement with any Bank or Financial Institution.

DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPT CODE, 2016 (31 OF 2016) DURING THE YEAR ALONG WITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR:

There is no proceeding pending under the Insolvency and Bankruptcy Code, 2016.

REPORTING OF FRAUDS BY AUDITORS:

There is no fraud reported in the Company during the Financial Year ended 31st March, 2022. This is also being supported by the report of the auditors of the Company as no fraud has been reported in their audit report for the Financial Year ended 31st March, 2022.

INTERNAL FINANCIAL CONTROLS:

The Company has put in place an internal financial control based on the processes involved in the Company. There is involvement from both management and functional/business spruces owner with periodic meetings to discuss issues, weaknesses, and progress of the company's internal financial control program.

The internal audit conducted for every quarter further scrutinizes the functioning of various areas of operations and gives its observation to the Audit Committee. Required action is taken based on the decision of the Audit Committee on the observations by the internal auditor.

Various processes like procurement, maintenance, marketing, accounting etc. are reviewed periodically both internally and by the internal auditors in a way which is commensurate with size & complexity of operations of the Company.

The above process helps the company in taking precautionary measures, making the existing process more efficient, bringing accuracy in accounting which enables orderly conduct of the business.

PARTICULARS OF EMPLOYEES

The details of the employees falling within the provisions of section 197 of the Companies Act, 2013 read with Rule 5(2) and 5(3) of The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

NAMES OF TOP 10 EMPLOYEES OF THE COMPANY IN TERMS OF REMUNERATION DRAWN
(OTHER THAN KEY MANAGERIAL PERSONNEL)

Sl.No.	Name	₹ p.m.
1.	Srinivasan G	53,500/-
2.	Sekar K	32,000/-
3.	Karthigai S	29,500/-
4.	Gunavathy K	29,000/-
5.	Rosline Leoni J	28,920/-
6.	Lissamma Jolly	28,000/-
7.	Mohan K	27,500/-
8.	Venkatesan G	27,026/-
9.	Manikandan.S	27,000/-
10	Saravanan.S	26,720/-

Disclosure pertaining to remuneration and other details as required under Section 197(12) of the Companies Act, 2013 read with Rule 5 (1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 for the year ended 31st March 2022.

Name	Designation and nature of duties	Age (years)	Qualification	Experience (years)	Last Employment & post held	Date of commencement of employment	Gross Remuneration (₹ in Lakhs)
Dr.V. Krishnamurthy*	Chief Executive Officer. Overall Management of the Company	65	M.D., D.M.,	41	Consultant, Rheumatologist, Apollo & Fortis Malar Hospital	01.01.2009	216.00 per annum

* Not a relative of any Director of the company. No. of Shares held : 1691 (0.02%)

DUES TO SMALL & MICRO ENTERPRISES

Dues outstanding more than ` 1,00,000/- to Small and Micro Industrial Units: Nil

SECRETARIAL STANDARDS OF ICSI

The Company is in compliance with the Secretarial Standards on Meetings of the Board of Directors (SS - 1) and General Meetings (SS - 2) issued by The Institute of Company Secretaries of India and approved by the Central Government.

INDUSTRIAL RELATIONS:

Human Resource is an important asset for the Company and there is cordial relationship exist between the management and the employees across the Company.

During the year your Company conducted various activities for the benefit of employees. An Awareness Program was organized for the employees. Many employees participated in the awareness program. A general medical camp was organized for the benefit of employees.

SOCIAL RESPONSIBILITY:

Your Company believes in importance of education in the growth of individuals and the economy as whole.

CORPORATE SOCIAL RESPONSIBILITY:

Corporate Social Responsibility provisions are not applicable to your company.

CAUTIONARY STATEMENT:

Shareholders and Readers are cautioned that in the case of data and information external to the Company, no representation is made on its accuracy or comprehensiveness though the same are based on sources believed to be reliable. Utmost care has been taken to ensure that the opinions expressed by the management herein contain its perceptions on the material impacts on the Company's operations, but it is not exhaustive as they contain forward-looking statements which are extremely dynamic and increasingly fraught with risk and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expressed herein.

ACKNOWLEDGMENT:

Your Directors place on record their appreciation for the continued support, assistance and co-operation extended to the Company by Government of Tamil Nadu, Government of India, Bankers and the Stakeholders. Your Directors also place on record their appreciation for the dedicated and continued performance and commitment by the Staff members and Executives of the Company.

For and on behalf of the Board

Place: Chennai
Date: 30th May, 2022

R. GOMATHI
Managing Director(DIN: 02900460)

ANNEXURES – TO DIRECTORS' REPORT

ANNEXURE-I

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Indian Healthcare Industry – An overview

The rising population and the overall economic development of India has developed the Healthcare sector to become one of the biggest sectors of Indian economy which has resulted in substantial improvement in terms of employment and revenue growth. Further the aged population with medical awareness coupled with lifestyle diseases are also other reasons for the growth of health sector. Health insurance coupled with the digital technologies are also showing good growth in this sector.

Government of India is also encouraging Foreign Direct Investment in this Sector. The Government of India has been announcing various policies involving several long-term measures to boost domestic manufacturing of pharmaceuticals and medical instruments.

The world-wide outbreak of Pandemic COVID 19 and its various forms has created number of opportunities for the growth of Healthcare Industry.

It has been observed that the Indian healthcare Industry which comprises of Hospitals, pharmaceuticals, diagnostics, medical instruments and health insurance are growing at a Compounded Annual Growth Rate of around 22%. It is also expected that the domestic diagnostic field is expected to grow steadily due to the changing forms of the Pandemic COVID 19. Various Global Healthcare players are treating India as a preferred country for their investment decisions.

The Pathology centres, miniaturized diagnostics and medical instruments have high potential for growth. Further, India's inherent strength in alternative system of medicine is also showing steady growth in both employment and financial. Medical Tourism is also showing significant growth for India's Healthcare Sector.

At present India has 1.3 hospital beds per 1,000 population. Though there are many institutions which provide training for skilled health workers, still there is also shortage of skilled workers. India needs additional 3 million beds to reach the target of at least 3 beds per 1,000 people in the coming years. Further, additional doctors and nurses are required to meet the growing demand in this Healthcare Industry.

Healthcare Sector – Outlook

Taking into account the growing population in India both rural and urban areas, private Healthcare players are expected to increase their investment in the healthcare industry to meet the additional demand for bed capacity, medical infrastructure. It is also expected that the healthcare services is expected to reach its next level with the help of technology advancements and other mobile technologies along with the fast growth of Internet.

Uncertainties and risks:

The various forms of COVID-19 pandemic has created a big strain on the world-wide workforce of the health sector. Because of the sudden ups and downs in the existence of the above Pandemic may result in uncertainties in the revenues of the health care sector. Frequent restrictions in gathering large number of people and the high rate of unemployment caused by the crisis will keep the revival slow.

In the more optimistic scenario, the earlier-than-expected success in combating the pandemic by enhancing testing, tracing and treatment options and signals of breakthroughs in vaccine development will lead to complete relaxation of restrictions in the near future. This gives hopes of revival and improvement in the coming years.

Strengths and Opportunities

Your Hospital is situated in the heart of the Chennai Metropolitan City which is prime strength for doing its business of healthcare for the ever growing population. The Company is able to continuously provide essential services even at this time of crisis due to the Pandamic COVID 19 which is yielding revenues. The visiting specialists from various healthcare fields are again strength of your hospital. Providing affordable cost of health treatments to all walks of people is again another arm of strength. Being in the heart of city with modern and quick electronic communication facilities help your company to run its business manageable even at this testing times due to severe problems created by the pandemic COVID-19 waves. This will strengthen the financials also to manage the increasing cost of management of your hospital.

Weakness and Threats:

The intensity of second wave and third wave of COVID-19 and its related diseases in Financial Year 2021-22 requires an emphasis on technology, digitization and information systems which involve huge investment which is lacking at the present juncture of economic slow down. Given the scenario, it may take some more time for the Company to bring its operating capacity to its optimum level. The Company believes the safety of its employees is most important at this stage which involves increased operational cost of providing the COVID-19 safety measures to all its medical professionals, para-medical professionals and the employees. Hence the Company has decided to cut cost wherever possible, increase the realization from certain activities to stay profitable. There is always a high risk that any unexpected incidents like the pandemic will play a crucial role in the performance.

Segment Wise Performance:

Your Company is in the business of providing only one segment viz. healthcare services. There is no change in the nature of business of the Company during the year under review. The following table gives an overview of the financial results of the Company:

(Amount - ₹ in Lakhs)

Particulars	31st March, 2022	31st March, 2021	Growth %
Gross Income	3177.53	2000.09	58.87
Profit/(Loss) before Depreciation, Tax & Financial Expenses	613.40	115.64	430.43
Interest	98.49	113.90	-13.52
Depreciation	117.32	126.72	-7.42
Profit/ (Loss) Before Tax	397.59	(124.98)	418.12
Less: Exceptional items	--	--	
Tax Expenses:			
a. Current Tax	--	--	
b. Fringe Benefit Tax	--	--	
c. Deferred Tax Liability	--	--	
Other Comprehensive Income			
(i) Items that will not be reclassified to profit or loss			
(a) Re-measurement of net defined benefit liability/Asset	1.76	4.01	
Profit/(Loss) for the year carried to Balance Sheet	399.35	(120.97)	430.12

The total revenue of the Company for the Financial Year 2021-22 is ₹ 3177.53 Lakhs compared to the total revenue of ₹ 2000.09 Lakhs in the previous year. The profit for the Financial Year 2021-2022 is ₹ 397.59 Lakhs as against a loss of ₹ (124.98) Lakhs in the previous year (excluding Other Comprehensive Income). The profit of the Company for the Financial Year 2021-2022 is ₹ 399.35 lakhs as against the loss After Tax of ₹ (120.97) Lakhs in the previous year. The other comprehensive income for the Financial Year 2021-2022 is ₹ 1.76 Lakhs as against ₹ 4.01 Lakhs in the previous year. The detailed over view of the Company's performance during the financial year 2021-22 is given in Annexure-I to the Directors Report - Management Discussion and Analysis Report. On approval by the Government of Tamilnadu to admit COVID 19 patients also your hospital has seen improvement during the months of May, 2021 and June, 2021 and again returned to normal performance subsequently.

Inspite of the hardships faced by the Company due to the consequences of the pandemic COVID-19 and its subsequent forms, your company managed to improve performance. Patients are approaching the hospital gradually after months of slowdown and we are expecting the performance improvement.

Financial Performance

The Financial and Operational performance of the Company are furnished in the Financial Statements as well as Board report.

Internal Control System

Your Company has an efficient in-built system to monitor the compliance of standards at each stage of the activities. The system enables the management to quickly identify any deviations from the required standards and to take appropriate action for correction. The compliance to the standards is also reviewed by the management periodically.

Material developments in Human Resources / Industrial Relations front, including number of people employed:

The primary objective of any human resource management is to ensure the availability of competent and willing work force to the organisation as well as to meet the needs, aspirations, values and dignity of individuals/employees and having due concern for the socio-economic problems of the people of the country. During the year, your company focused on these objectives keeping in mind the disastrous COVID PANDEMIC that has shaken the entire economy. The employees are provided competitive compensation, growth opportunities and other benefits for their association with the Company for a longer period. The Company's total strength of employees is 234 as on 31st March, 2022 (Previous year-231). There have been no major disputes during the financial year and the Company enjoys cordial relationship with all its employees.

Risks and Concerns

The Company has in place a Risk Management Policy duly approved by the board which is periodically reviewed by the management. The main objective of the company's risk management policy is to ensure the effective identification and reporting of risk exposures, involvement of all departments and employees in risk management, to ensure continuous growth of business and protect all the stakeholders of the Company. Based on the current business environment below are the major risks and its impact identified by the Company and the measures taken for mitigation.

Risks Impact on the Company-Mitigation Strategy

Uncertainty in the business environment caused by Covid-19.

With many economies slowing down due to the Pandemic the performance of the company may also shrink. The company take measures to mitigate the risk. Some of the measures are employing local labourers wherever possible.

Doing cost cutting exercise to stay profitable.

Engaging with Doctors/medical professionals for pricing based on current market conditions.

Currency Risks: The Currency Risk is very negligible for the Company.

Key Financial Ratios

In accordance with the SEBI (Listing Obligations and Disclosure Requirements 2018) (Amendment) Regulations, 2018, the Company is required to give details of significant changes (change of 25% or more as compared to the immediately previous financial year) in key sector specific financial ratios.

The revenue of the Company for the Financial Year 2021-22 is ₹ 3177.53 lakhs increase by 58.87% over the previous year revenue of ₹ 2000.09 Lakhs. The Profit Before Tax for the Financial Year 2021-22 is ₹ 397.59 Lakhs against loss of ₹ 124.98 Lakhs for Financial Year 2020-21 increased by 418.12%. The PAT of the Company for Financial Year 2021-22 is ₹ 399.35 lakhs as against loss of ₹ 120.97 Lakhs in Financial Year 2020-21 increase by 430.12%.

Future Outlook:

The demand for healthcare services in India is likely to remain robust in the foreseeable future subject to the COVID-19 pandemic situations. The pick in the economic activity depends on how the pandemic continues to affect the countries, its treatment and vaccine development according to the needs of the waves of COVID-19. Your Company is taking measures to contain the risks impacting its operations as discussed above and improve its performance.

DETAILS OF IN PATIENTS AND OUT PATIENTS FOR 2020-21 AND 2021-22

Year	Inpatients	Outpatients	Total
2020-21	2486	25982	28468
2021-22	2927	27384	30311

CAUTIONARY STATEMENT

Statements contain in this report describing the Company's objectives, expectations or predictions may be forward looking within the meaning of applicable laws and regulations. The actual results may differ materially from those expressed in this statement because of many factors like economic condition, availability of labour, price conditions, domestic and international market, etc.

For and on behalf of the Board

Place: Chennai

Date: 30th May, 2022

R. GOMATHI
Managing Director
(DIN: 02900460)

ANNEXURE II

T. MURUGAN, B.Sc., ACA., ACS.
Company Secretary in Practice

M22-E, Sri Subah Colony, Munusamy Road,
K.K.Nagar, Chennai-600078.
Ph: 044-2366 1875, 93810 35900.
E-Mail: murugantmp@yahoo.co.in;
murugan.thirumalpillai@gmail.com

Form No. MR-3

SECRETARIAL AUDIT REPORT
[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of the Companies (Appointment and Remuneration of Personnel) Rules, 2014]

FOR THE FINANCIAL YEAR ENDED 31.03.2022

To
The Members,
Chennai Meenakshi Multispeciality Hospital Limited

I have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/S. Chennai Meenakshi Multispeciality Hospital Limited (Hereinafter called the "Company"). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the company has during the audit period covering the financial year ended on 31.03.2022, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by Chennai Meenakshi Multispeciality Hospital Limited for the financial year ended on 31.03.2022 according to the provisions of:

(i) The Companies Act, 2013 (the "Act") and the rules made there under;
(ii) The Securities Contracts (Regulation) Act, 1956 and the rules made there under;
(iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
(iv) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):
    (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
    (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
    (c) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(v) The Other laws specifically applicable to this Company are as follows:
    (a) Chennai City Municipal Corporation Act, 1919
    (b) The Drugs & Cosmetics Act 1940
    (c) Shops and Establishment Act
    (d) Environment (Protection) Act, 1936 and Bio-Medical waste (Managing and Handling) Rules, 1998

I have also examined compliance with the applicable clauses of the following:

(i) Listing Agreement entered into by the Company with Bombay Stock Exchange.
(ii) Secretarial Standards on Meeting of the Board of Directors (SS-1) and General Meetings (SS-2) issued by the Institute of Company Secretaries of India (ICSI).

I report that, during the year under review, the Company has complied with the provisions of the Acts, rules, regulations and guidelines mentioned above.

I further report that, there were no actions/events in pursuance of:

a) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008:
b) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018,
c) The Securities and Exchange Board of India (Share based Employee Benefits), 2014.
d) The Securities and Exchange Board of India (Registrars to Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with Client;
e) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009
f) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 requiring compliance thereof by the company during the financial year.

I further report that, based on the information provided by the Company, its officers and authorised representatives during the conduct of audit, in my opinion, adequate systems and processes and control mechanism exist in the company to monitor and ensure compliance with general laws like Labour and Environmental Laws.

I further report, that the compliance by the Company of applicable financial laws, like direct and indirect tax laws are subjected to review by statutory financial audit and other designated professionals.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

I further report that

The Board of Directors of the Company is duly constituted with Proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least Seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

As per the minutes of the meetings duly recorded and signed by the Chairman, the decisions of the Board were unanimous and no dissenting views have been expressed.

I further report that there are adequate systems and processes in the Company commensurate with the size and Operations of the Company to monitor and ensure compliance with Applicable laws, rules, regulations and guidelines.

Place: Chennai
Date 30th May, 2022

T. Murugan
Company Secretary in Practice
Membership no: A11923/C.P No. 4393
UDIN: A011923D000424907

Annexure - A

To

The Members,
M/S. Chennai Meenakshi Multispecialty Hospital Limited
149, Luz Church Road, Mylapore,
Chennai – 600004

1. Maintenance of secretarial records is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.

2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on the random test basis to ensure that the correct facts are reflected in secretarial records, we believe that the processes and practices, we followed provide a reasonable basis for our opinion.

3. We have not verified the correctness and appropriateness of financial records and books of accounts of the company.

4. Wherever required, we have obtained the management representation about the compliance of laws, rules and regulations and happening of events etc.

5. The compliance of the provisions of the management of corporate and other applicable laws, rules, regulations, standards is the responsibility of the management; our examination was limited to the verification of procedures on a random test basis.

6. The secretarial audit report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with the management has conducted the affairs of the company

Place: Chennai
Date: 30th May, 2022

T. Murugan
Company Secretary in Practice
Membership no: A11923 / C.P No. : 4393
UDIN: A011923D000424907

T. MURUGAN, B.Sc., ACA., ACS.
Company Secretary in Practice

M22-E, Sri Subah Colony, Munusamy Road,
K.K.Nagar, Chennai-600078.
Ph: 044-2366 1875, 93810 35900.
E-Mail: murugantmp@yahoo.co.in;
murugan.thirumalpillai@gmail.com

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEB(Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The Members of Chennai Meenakshi Multispeciality Hospital Limited,
Old No.149, New No.70, Luz Church Road, Mylapore,
Chennai 600004.

I have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Chennai Meenakshi Multispeciality Hospital Limited having CIN L85110TN1990PLC019545 and having registered office at New No.70, Old No.149, LUZ Church Road, Mylapore, Chennai - 600004 and (hereinafter referred to as 'the Company'), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to me by the Company & its officers, I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2022 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other Statutory Authority.

S. No	Name of the Director	DIN	Date of appointment in Company
1.	Mr. AthiyurNatesan Radhakrishnan	01508867	29/04/2007
2.	Mrs. Gomathi Radhakrishnan	02900460	05/05/2018
3.	Mr. Krishnamurthy Meyyanathan	07845698	20/05/2021
4.	Mr. Nagayasamy Rajkumar	00617000	09/06/2021

Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

Place: Chennai
Date: 30th May, 2022

T. Murugan
Practising Company Secretary
Membership no: A11923
C.P No. : 4393
UDIN: A011923D000425105

ANNEXURE-III

FORM NO AOC-2

Form for disclosure of particulars of contracts/ arrangements entered into by the company with related parties referred to in sub-section (1) of Section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto.

(Pursuant to clause (h) of subsection (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

1. Details of Contracts/ Arrangements/ transactions not at arm's length basis

(a) Name(s) of the related party & nature of relationship (b) Nature of contracts/arrangements/transactions (c) Duration of contracts/arrangements/transactions (d) Salient terms of contracts/arrangements/transactions including the value, if any (e) Justification for entering into such contracts/arrangements / transactions (f) Date(s) of approval by the board (g) Amount paid as advance(s), if any: (h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188.	NIL

2 .Details of Contracts/ Arrangements/ transactions at arm's length basis:

S. NO	Name of Related party/ Nature of Relationship	Nature of Contract	Amount (₹)	Duration of contract	Date(s) of approval by the board	Amount paid as advances, if any:
1.	Mr. A.N. Radhakrishnan Director (DIN: 01508867)	Rendering of Services	1,632,045	2021-2022	31.03.2021	NIL
2.	Mrs. R. Gomathi, Managing Director, (DIN:02900460) W/O.Mr.A.N.Radhakrishnan	Receiving of Services (Salary)	9,00,000	2021-2022	31.03.2021	NIL
3.	Mrs. R. Gomathi, Managing Director, (DIN:02900460) W/O.Mr.A.N.Radhakrishnan	Rendering of Services	7,180	2021-2022	31.03.2021	NIL
4.	Mr. A.N. Radhakrishnan Director (DIN: 01508867)	Interest on Loan	77,09,481	2021-2022	29-07-2006 13-02-2013 31.03.2021	Not Applicable
5.	Mrs. R. Gomathi, Managing Director, (DIN:02900460) W/O.Mr.A.N.Radhakrishnan	Leasing arrangements	300,000	2021-2022	31.03.2021	Nil
6.	Enterprises in which directors are interested:					
	1. Meenakshi Ammal Trust.	Leasing Arrangements	6,000,000	2021-2022	31.03.2021 13.08.2021	Nil
	2. Sri Muthukumaran Educational Trust.	Leasing arrangements	300,000	2021-2022	31.03.2021	Nil
	Mr. A.N. Radhakrishnan and Mrs. R. Gomathi are interested in the above trusts					

For and on behalf of the Board

Place: Chennai
Date: 30th May, 2022

R. GOMATHI
MANAGING DIRECTOR - DIN:02900460

ANNEXURE - IV

FORM-A

Statement of Particulars of Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo required under the Companies (Accounts) Rules, 2014.

A. Power and Fuel Consumption	As on 31.03.2022	As on 31.03.2021
01.Electricity		
(a) Purchased		
Units	594265	557349
Total Amount(₹)	5,246,083	4,696,848
Rate/unit (₹)	8.82	8.43
(b) Own Generation		
Through Diesel generators		
Units	17606	6772
Unit per-litre of Diesel oil	3.69	3.95
Cost/Unit (₹)	24.86	20.68
02. Coal	**N.A.**	**N.A.**
03. Furnace Oil	**N.A.**	**N.A.**
Consumption per unit of Production	**N.A.**	**N.A.**

FORM-B

B. TECHNOLOGY ABSORPTION

(Form for disclosure of particulars with respect to Technology Absorption)

	As on 31.03.2022 (₹)	As on 31.03.2021 (₹)
Research and Development (R&D):	NIL	NIL
Expenditure on R&D:	NIL	NIL
Technology Absorption, Adoption and Innovation:	NIL	NIL

C. FOREIGN EXCHANGE EARNINGS AND OUTGO:

	As on 31.03.2022 (₹)	As on 31.03.2021 (₹)
a. Total Foreign Exchange earned	NIL	NIL
b. Foreign Exchange outgo	NIL	NIL

CEO and CFO certification

The Board of Directors,
Chennai Meenakshi Multispeciality Hospital Limited,
Chennai.

Dear Members of the Board,

We, Dr. V.Krishnamurthy, Chief Executive Officer and Mr. Dambaru Dhar Jena, Chief Financial Officer of Chennai Meenakshi Multispeciality Hospital Limited, to the best of our knowledge and belief, certify that:

1. We have reviewed the Balance Sheet, Statement of Profit and Loss and Cash Flow Statement of the Company and all the notes on accounts and the Board's report for the year ended 31st March, 2022.

2. These statements do not contain any materially untrue statement or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3. The financial statements and other financial information included in this report, present in all material respects a true and fair view of the Company's affairs, the financial condition, results of operations and cash flows of the Company as at, and for, the periods presented in this report, and are in compliance with the existing Accounting Standards and / or applicable laws and regulations.

4. There are no transactions entered into by the Company during the year that are fraudulent, illegal or violate the Company's Code of Conduct and Ethics, except as disclosed to the Company's auditors and the Company's audit committee of the Board of Directors.

5. We are responsible for establishing and maintaining disclosure controls and procedures and internal controls over financial reporting for the Company, and we have:

a. Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the Company, is made known to us by others within those entities, particularly during the period in which this report is being prepared.

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with Generally Accepted Accounting Principles (GAAP) in India.

c. Evaluated the effectiveness of the Company's disclosure, controls and procedures.

d. Disclosed in this report, changes, if any, in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal year that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

6. We have disclosed, based on our most recent evaluation of the Company's internal control over financial reporting, wherever applicable, to the Company's auditors and the audit committee of the Company's Board (and persons performing the equivalent functions):

a. Any deficiencies in the design or operation of internal controls, that could adversely affect the Company's ability to record, process, summarize and report financial data, and have confirmed that there have been no material weaknesses in internal controls over financial reporting including any corrective actions with regard to deficiencies.

b. Any significant changes in internal controls during the year covered by this report.

c. All Significant changes in accounting policies during the year, if any, and the same have been disclosed in the notes to the financial statements.

d. Any instances of significant fraud of which we are aware, that involve the Management or other employees who have a significant role in the Company's internal control system.

7. We affirm that we have not denied any personnel access to the audit committee of the Company (in respect of matters involving alleged misconduct) and we have provided protection to whistleblowers from unfair termination and other unfair or prejudicial employment practices.

8. We further declare that all Board members and senior management personnel have affirmed compliance with the Code of Conduct and Ethics for the year covered by this report.

Place: Chennai	Dr.V.Krishnamurthy	Mr. Dambaru Dhar Jena
Date: 30th May, 2022	Chief Executive Officer	Chief Financial Officer

INDEPENDENT AUDITOR'S REPORT

To the Members of

M/s. CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LTD
Chennai.

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LTD ("the company"), which comprises the standalone balance sheet as at 31 March 2022 and the standalone statement of profit and loss (including other comprehensive income), standalone statement of changes in equity and standalone statement of cash flows for the year then ended and notes to the standalone financial statements, including a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2022, and its profit, total comprehensive income, the changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibility for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

Key Audit Matter	Auditor's Response
Revenue from the sale of Medicine (hereinafter referred to as "Revenue") is recognised when the Company performs its obligation to its customers and the amount of revenue can be measured reliably and recovery of the consideration is probable. The timing of such recognition in case of sale of Medicine is when the control over the same is transferred to the customer, which is mainly upon delivery. The timing of revenue recognition is relevant to the reported performance of the Company. The management considers revenue as a key measure for evaluation of performance. There is a risk of revenue being recorded before control is transferred. Refer Note 1 to the Standalone Financial Statements - Significant Accounting Policies	In view of the significance of the matter we applied the following audit procedures in this area, among others to obtain sufficient appropriate audit evidence: A. Obtaining an understanding of and assessing the design, implementation and operating effectiveness of management's key internal controls relating to the recognition of revenue, including those related to the reconciliation of sales records to cash / credit card / online receipts, preparation, posting and approval of manual journal entries relating to revenue recognition. B. Testing the accuracy of retail revenue recorded during the year by examining that the sale of goods transactions are in agreement with the cash / credit card / online receipts and deposit of cash amounts recorded in daily cash reports with bank remittances, on sample basis. C. Obtaining reconciliation of sales as per books of account with the sales as per Indirect tax records and inquire about reasons for differences, if any.

Other Information

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's annual report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of Assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements

The Company's management and Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs, profit/loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of mostsignificance in the audit of the standalone financial statements of the current period and are therefore the key audit matters.We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies(Auditor's Report) Order,2020 ("the Order") issued by the Central Government of India in terms of sub-section(11) of section 143 of the Act, we give in "Annexure", a statement on the matters specified in paragraphs 3 and 4 of the Order.

As required by Section 143(3) of the Act, we report that:

(a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;

(b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examinations of those books and proper returns adequate for the purposes for our audit have been received from the branches not visited by us;

(c) In our opinion, proper books of account as required by the law have been kept by the company so far as it appears from our examination of those books and proper returns adequate for the purposes of our audit have been received from the branches not visited by us;

(d) The Balance Sheet, the Statement of Profit and Loss, the Cash Flow Statement and Statement of Changes in Equity dealt with by this report are in agreement with the books of account and with the returns received from the branches not visited by us;

(e) In our opinion, the aforesaid Ind AS financial statements comply with the Indian Accounting Standards prescribed under Section 133 of the Act;

(f) On the basis of the written representations received from the directors as on 31 March, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March, 2022 from being appointed as a director in terms of Section 164(2) of the Act;

(g) With respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls, refer to our separate Report in “Annexure-B”;

2. With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to explanations given to us:

i. The Company did not have any pending litigations ;

ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;

iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

FOR MRC& ASSOCIATES
CHARTERED ACCOUNTANTS
Firm Registration No.: 004005S

G. CHIRANJEEVULU, FCA
PARTNER
Membership.No.215032
UDIN : 22215032ANJMIW9993

Place: Chennai
Date: 30.05.2022

Annexure A referred in the Independent Auditor's Report to the Members of CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LTD on the standalone Ind AS financial statements for the year ended 31 March 2022

i.

a. The Company has maintained proper records showing full particulars, including quantitative details and situation of property, plant and equipment – Refer para 3(1)(a)(A) of CARO 2020.

b. The property, plant and equipment were physically verified during the year by the Management in accordance with a regular programme of verification which, in our opinion, provides for physical verification of all the property, plant and equipment at reasonable intervals. According to the information and explanations given to us, no material discrepancies were noticed on such verification – Refer para 3(i)(a)(A) of CARO 2020

c. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of the immovable properties included in the fixed assets are held in the name of the Company. However we express no opinion of the validity of the title of the company to these properties – Refer para 3(i)(c) of CARO 2020.

ii. The company does not have any intangible assets as on the balance sheet date. Accordingly, para 3(i)(a)(B) and Para 3(i)(d) of CARO 2020 is not applicable.

iii. According to the information given to us and on the basis of our examination of the records of the company, no proceedings has been initiated or pending against the company for holding any benami properties. Accordingly, para 3(i)(e) of CARO 2020 is not applicable.

iv. As explained to us, the inventories other than material lying with third parties (which have substantially been confirmed) were physically verified during the year by the Management at reasonable intervals and no material discrepancies were noticed on such physical verification - refer para 3(ii)(a) of CARO 2020.

v. According to information and explanation given to us and on the basis of our examination of books and records, The company has not availed any working capital limit from banks/financial institutions. Accordingly, para 3(ii)(b) of CARO 2020 is not applicable.

vi. The Company has not granted any loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or other parties covered in the Register maintained under Section 189 of the Companies Act, 2013. Accordingly, para 3(iii) of CARO 2020 is not applicable.

vii. The company has not entered into any transaction in respect of loans, investments, guarantees and security to which the provisions of Section 185, 186 of the Act would apply. Accordingly, para 3(iv) of CARO 2020 is not applicable

viii. According to the information and explanations given to us, the Company has not accepted any deposits covered under Section 73 to 76 of the Act. Accordingly, para 3(v) of CARO 2020 is not applicable.

ix. According to the information and explanations given to us, the Central Government has not specified the maintenance of cost records under Section 148(1) of the Companies Act, 2013, for the products of the Company. Accordingly, para 3(vi) of CARO 2020 is not applicable.

x.

a. *According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted / accrued in the books of account in respect of undisputed statutory dues including Provident Fund, Employees' State Insurance, Income tax, Sales tax, Service tax, Duty of Customs, Duty of Excise, Goods and Service Tax ('GST'), Value Added Tax, Cess and any other material statutory dues, to the extent applicable, have generally been regularly deposited with the appropriate authorities during the year. As explained to us, the Company did not have any dues on account of Sales tax, Service tax, Duty of excise, Value Added Tax and Cess* – refer para 3(vii) of CARO 2020.

b. According to the records of the company, there are no dues of income tax, Goods and Service tax, duty of customs, value added tax which have not been Deposited with the appropriate authorities on account of any dispute – refer para 3(viii) of CARO 2020.

xi. There were no transactions relating to previously unrecorded income that were surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961 (43 of 1961) during the year. Accordingly, para 3(xviii) of CARO 2020 is not applicable.

xii. Based on our audit procedures performed for the purpose of reporting the true and fair view of the financial statements and according to the information and explanations given to us, the company has not defaulted in repayment of dues to the Bank. The company has not obtained any loans from financial institutions, government and debenture holders. Accordingly, para 3(ix)(a)/(b) of CARO 2020 is not applicable.

xiii. According to the information and explanation given to us and basis of examination of books of accounts of the company, the company has not availed any term loan from bank/financial institution. Accordingly, Para 3(ix)(c) of CARO 2020 is not applicable.

xiv. According to the information and explanation given to us and basis of examination of books of accounts of the company, the company does not have any short term borrowings. Accordingly, para 3(ix)(d) of CARO 2020 is not applicable.

xv. According to information and explanation given to us, the company has not taken any funds from any entity or person to meet obligation of its subsidiaries, associates or joint ventures during the year under report. Accordingly, para 3(ix)(e) of CARO 2020 is not applicable.

xvi. According to information and explanation given to us, the company has not raised any loans on pledge of securities held in its subsidiaries, associates or joint ventures during the year under report. Accordingly, para 3(ix)(f) of CARO 2020 is not applicable

xvii. a. According to the information and explanations given to us, the Company has not raised any money by way of initial public offer or further public offer (including debt instrument) and any term loans during the year. Accordingly, paragraph 3 (x)(a) of CARO 2020 is not applicable.

b. According to information and explanations given to us, and on the basis of our examination of the records of the Company has not made any

preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, paragraph 3(x)(b) of CARO 2020 is not applicable.

xviii. According to the information and explanations given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the year. Accordingly, para 3(xi) of CARO 2020 is not applicable.

xix. According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, paragraph 3(xii) of the CARO 2020 is not applicable.

xx. According to the information and explanations given to us and based on our examination of the records of the Company, the managerial remuneration has been paid or provided by the Company in accordance with the provisions of Section 197 read with Schedule V to the Act.

xxi. According to information and explanations given to us and on the basis of our examination of the records of the Company, all transactions with the related parties are in compliance with Section 177 and 188 of the Act, where applicable, and the details have been disclosed in the Ind AS financial statements, as required by the applicable accounting standard– refer para 3(xiii) of CARO 2020.

xxii. a. In our opinion, the Company has an adequate internal audit system commensurate with the size and the nature of its business.
b. We have considered, the internal audit reports for the year under audit and till date, in determining the nature, timing and extent of our audit procedures - refer Para 3(xiv) of CARO 2020.

xxiii. According to information and explanations given to us, the Company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, paragraph 3(xv) of the CARO 2020 is not applicable.

xxiv. According to information and explanations given to us, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. accordingly para 3(xvi) of CARO 2020 not applicable

xxv. The company has not incurred any cash loss during the financial year covered by our audit and also in the preceding Financial year. Accordingly, para 3(xvii) of CARO 2020 is not applicable.

xxvi. There has been no resignation of the statutory auditors of the Company during the year under report . Accordingly para 3(xviii) CARO 2020 not applicable.

xxvii. According to information and explanation given to us and on the basis of examination of books of accounts of company and financial ratios ageing and realisation of financial assets, we are of the opinion no material uncertainty exist as on the date of audit report and the company is capable of meeting its liabilities existing on the date of balance sheet and also falls due within a period of one year from the balance sheet date – refer Para 3(xix) of CARO 2020.

xxviii. According to information and explanation give to us and on the basis of examination of books of accounts of the company CSR rules does not apply to this company. Accordingly transfer of unspent CSR funds para 3(xx) of CARO 2020 not applicable .

FOR MRC & ASSOCIATES
CHARTERED ACCOUNTANTS
Firm Registration No.: 004005S

G. CHIRANJEEVULU, FCA
PARTNER
Membership.No.215032
UDIN: 22215032ANJMIW9993

Place: Chennai
Date: 30th May, 2022

Annexure B to the Independent Auditor's report on the standalone financial statements of CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LTD for the year ended 31 March 2022

Report on the internal financial controls with reference to the aforesaid standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013

(Referred to in paragraph 1(A) (g) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We have audited the internal financial controls with reference to financial statements of CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LTD ("the Company") as of 31 March 2022 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31 March 2022, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

Management's Responsibility for Internal Financial Controls

The Company's management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (hereinafter referred to as "the Act").

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under section 143(10) of

the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included, obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Meaning of Internal Financial controls with Reference to Financial Statements

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes inaccordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail,accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial controls with Reference to Financial Statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also,

projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

FOR MRC & ASSOCIATES
CHARTERED ACCOUNTANTS
Firm Registration No.: 004005S

G. CHIRANJEEVULU, FCA
PARTNER
Membership.No.215032
UDIN: 22215032ANJMIW9993

Place: Chennai
Date: 30th May, 2022

CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LIMITED

(FORMERLY KNOWN AS DEVAKI HOSPITAL LIMITED)

CIN: L85110TN1990PLC019545

New No.70, Old No.149, Luz Church Road, Mylapore, Chennai-600 004

BALANCE SHEET AS ON 31 MARCH 2022

(All figures are in Indian Rupees unless otherwise stated)

	Particulars	Note No	As on 31.03.2022	As on 31.03.2021
I	**ASSETS**			
	NON - CURRENT ASSETS			
	(a) Property, Plant and Equipment	**2**	140,765,759	128,677,134
	(b) Capital Work-in-progress		-	1,197,960
	(c) Other Non-Current Assets	**3**	2,516,998	2,516,998
II	**CURRENT ASSETS**			
	(a) Inventories	**4**	3,964,669	5,774,118
	(b) Financial Assets			
	(i) Trade Receivables	**5**	9,205,240	7,885,550
	(ii) Cash and Cash Equivalents	**6**	32,366,758	30,974,825
	(iii) Others - Short term loans and advances		-	-
	(c) Other Current Assets	**7**	25,052,659	14,986,492
	TOTAL ASSETS		**213,872,083**	**192,013,077**
	EQUITY AND LIABILITIES			
	EQUITY			
	(a) Equity Share Capital	**8**	74,689,200	74,689,200
	(b) Other Equity	**9**	(82,457,497)	(122,392,000)
	LIABILITIES			
I	**Non-Current Liabilities**			
	(a) Financial Liabilities			
	(i) Borrowings	**10**	106,263,826	114,763,826
	(b) Provisions	**11**	8,087,010	6,769,953
II	**Current Liabilities**			
	(a) Financial Liabilities			
	(i) Trade Payables	**12**	-	-
	- total outstanding dues of micro enterprises and small enterprises		-	-
	- total outstanding dues of creditors other than micro enterprises and small enterprises		20,184,028	15,039,867
	(b) Other Current Liabilities	**13**	86,032,043	101,651,159
	(c) Provisions	**14**	1,073,473	1,491,072
	TOTAL EQUITY AND LIABILITIES		**213,872,083**	**192,013,077**

Significant Accounting Policies and Notes on accounts **1 to 31**

As per our report of even date attached

For and on behalf of the Board of Directors

For MRC AND ASSOCIATES
Chartered Accountants
Firm Registration No.: 004005S

G. Chiranjeevulu
Partner
Membership No.: 215032

Place: Chennai
Date: 30.05.2022
UDIN: 22215032ANJMIW9993

A.N. Radhakrishnan
Director
DIN :01508867

Dr. V. Krishnamurthy
Chief Executive Officer
PAN: ABAPK5242M

Dambaru Dhar Jena
Chief Financial Officer
PAN: AHOPD5875H

Gomathi Radhakrishnan
Managing Director
DIN: 02900460

R. Deenadayalu
Company Secretary
Membership No.: F3850

Place: Chennai
Date: 30.05.2022

CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LIMITED

(FORMERLY KNOWN AS DEVAKI HOSPITAL LIMITED)

CIN:L85110TN1990PLC019545

New No.70, Old No. 149, Luz Church Road, Mylapore, Chennai- 6000 004

PROFIT & LOSS STATEMENT FOR THE YEAR ENDED 31 MARCH 2022

(All figures are in Indian Rupees unless otherwise stated)

	Particulars	Note No	31st March 2022	31st March 2021
I	Revenue from Operations	15	313,863,028	194,818,733
II	Other Income	16	3,890,682	5,190,586
III	**Total Income [I + II]**		**317,753,710**	**200,009,319**
IV	**EXPENSES**			
	Purchases of Stock In Trade		67,803,034	45,642,731
	Changes in Inventories of Finished Goods	17	1,809,449	1,065,760
	Employee Benefits Expenses	18	82,715,501	69,230,743
	Finance Costs	19	9,849,200	11,389,958
	Depreciation and amortization expenses	2	11,732,028	12,672,098
	Other Expenses	20	104,085,799	72,505,216
IV	**Total Expenses**		**277,995,011**	**212,506,505**
V	**Profit /(Loss) before tax and Exceptional Items [III - IV]**		**39,758,699**	**(12,497,186)**
VI	Exceptional Items		**-**	**-**
VII	**Profit/(Loss) before tax (V - VI)**		**39,758,699**	**(12,497,186)**
VIII	**Tax Expenses:**			
	(1) Current Tax		-	-
	(2) Deferred Tax		-	-
IX	**Profit/(Loss) for the year from continuing operations (VII - VIII)**		**39,758,699**	**(12,497,186)**
X	**Profit/(loss) from discontinued operations**			
XI	**Tax expenses of discontinued operations**			
XII	**Profit/(loss) from Discontinued operations (after tax) (X-XI)**			
XIII	**Profit/(loss) for the period (IX+XII)**			
XIV	**Other Comprehensive Income**			
	[A] (i) Items that will not be reclassified to profit or loss		175,804	**400,548**
	(ii) Income Tax relating to items that will not be reclassified to profit or loss			
	[B] (i) Items that will be reclassified to profit or loss			
	(ii) Income Tax relating to items that will be reclassified to profit or loss			
XV	**Total Comprehensive Income for the Period (IX + X) (Comprising Profit (Loss) and other Compreshensive Income for the Period)**		**39,934,503**	**(12,096,638)**
XVI	**Earings Per Equity Share (for Discontinued Operation)**	21		
	Basic		-	-
	Diluted		-	-
XVII	**Earings Per Equity Share (for Discontinued & Continuing Operation)**	21		
	Basic		5.32	(1.67)
	Diluted		5.32	(1.67)

Significant Accounting Policies and Notes on accounts **1 to 31**

As per our report of even date attached

For MRC AND ASSOCIATES
Chartered Accountants
Firm Registration No.: 004005S

G. Chiranjeevulu
Partner
Membership No.: 215032

Place: Chennai
Date: 30.05.2022
UDIN: 22215032ANJMIW9993

For and on behalf of the Board of Directors

A.N. Radhakrishnan
Director
DIN :01508867

Dr. V. Krishnamurthy
Chief Executive Officer
PAN: ABAPK5242M

Dambaru Dhar Jena
Chief Financial Officer
PAN: AHOPD5875H

Gomathi Radhakrishnan
Managing Director
DIN: 02900460

R. Deenadayalu
Company Secretary
Membership No.: F3850

Place: Chennai
Date: 30.05.2022

CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LIMITED

(FORMERLY KNOWN AS DEVAKI HOSPITAL LIMITED)

CIN:L85110TN1990PLC019545

New No.70, Old No. 149, Luz Church Road, Mylapore, Chennai- 6000 004

Statement of Changes in Equity for the year ended 31 March 2022

A EQUITY SHARE CAPITAL

[1] For the Year ended March 31, 2022 ***(All figures are in Indian Rupees unless otherwise stated)***

Balance at April 01, 2021	Changes in Equity Share Capital due to prior period errors	Restated balance at April 01, 2021	Changes in equity share capital during the year	Balance at March 31, 2022
150,000,000	-	150,000,000	-	150,000,000

[2] For the Year ended March 31, 2021

Balance at April 01, 2020	Changes in Equity Share Capital due to prior period errors	Restated balance at April 01, 2020	Changes in equity share capital during the year	Balance at March 31, 2021
150,000,000	-	150,000,000	-	150,000,000

B OTHER EQUITY

[1] For the Year ended March 31, 2022

PARTICULARS	Capital Total Reserve	Securities Premium	Retained Earnings	Total
Balance at April 01, 2021	273,200	5,710,830	(128,376,031)	(122,392,001)
Changes in accounting policy or prior period errors	-	-	-	-
Restated balance April 01, 2021	-	-	-	-
Total Comprehensive Income for the year	-	-	175,804	175,804
Dividends	-	-	-	-
Transfer to retained earnings	-	-	39,758,699	39,758,699
Any other change (to be specified)	-	-	-	-
Balance at March 31, 2022	273,200	5,710,830	(88,441,528)	(82,457,498)

[2] For the Year ended March 31, 2021

PARTICULARS	Capital Total Reserve	Securities Premium	Retained Earnings	Total
Balance at April 01, 2020	273,200	5,710,830	(116,279,393)	(110,295,363)
Changes in accounting policy or prior period errors	-	-	-	-
Restated balance April 01, 2020	-	-	-	-
Total Comprehensive Income for the year	-	-	400,548	400,548
Dividends	-	-	-	-
Transfer to retained earnings	-	-	(12,497,186)	(12,497,186)
Any other change (to be specified)	-	-	-	-
Balance at March 31, 2021	273,200	5,710,830	(128,376,031)	(122,392,001)

Significant Accounting Policies and Notes on accounts **1 to 31**

As per our report of even date attached

For MRC AND ASSOCIATES
Chartered Accountants
Firm Registration No.: 004005S

G. Chiranjeevulu
Partner
Membership No.: 215032

Place: Chennai
Date: 30.05.2022
UDIN: 22215032ANJMIW9993

For and on behalf of the Board of Directors

A.N. Radhakrishnan
Director
DIN :01508867

Dr. V. Krishnamurthy
Chief Executive Officer
PAN: ABAPK5242M

Dambaru Dhar Jena
Chief Financial Officer
PAN: AHOPD5875H

Gomathi Radhakrishnan
Managing Director
DIN: 02900460

R. Deenadayalu
Company Secretary
Membership No.: F3850

Place: Chennai
Date: 30.05.2022

CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LIMITED

(FORMERLY KNOWN AS DEVAKI HOSPITAL LIMITED)

CIN:L85110TN1990PLC019545

New No.70, Old No.149,Luz Church Road, Mylapore, Chennai-600 004

CASH FLOW STATEMENT FOR THE YEAR 2021-22

(All figures are in Indian Rupees unless otherwise stated)

Particulars	2021-22	2020-21
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit / (Loss) from Continuing Operations	39,934,503	(12,096,638)
Adjustments for :		
Depreciation	11,732,028	12,672,098
Adjustments for Income Tax	-	-
Interest charged to Statement of Profit & Loss	7,716,959	9,763,694
Interest income	(771,118)	(1,398,346)
(Profit) / Loss on sale of assets	204,781	8,031
Bad Debts written off	44,507	1,117,682
Operating profit before Working Capital changes	**58,861,661**	**10,066,518**
Changes in Working Capital		
(Increase) or Decrease in Inventories	1,809,449	1,065,760
(Increase) or Decrease in Trade and other Receivables	(1,364,197)	1,580,270
(Increase) or Decrease in other Current Assets	(10,066,167)	10,685,127
(Increase) or Decrease in other Non - Current Assets	-	(10,000)
Increase or (Decrease) in Trade Payables	5,144,161	3,612,793
Increase or (Decrease) in Other Current Liabilities	(16,036,715)	4,997,527
Increase or (Decrease) in Other Non - Current Liabilities	1,317,057	1,003,027
Net Cash Flow from Operating Activities Total(A)	**39,665,249**	**33,001,022**
B. CASH FLOW FROM INVESTING ACTIVITIES		
Proceeds from Sale of Property, Plant and Equipment	42,373	4,000
Purchase of Property, Plant and Equipment	(24,067,806)	(2,806,184)
Capital WIP Written off	1,197,960	-
Interest income	771,118	1,398,346
Net Cash Flow Used in Investing Activities Total (B)	**(22,056,355)**	**(1,403,838)**
C. CASH FLOW FROM FINANCING ACTIVITIES		
Repayments of borrowings	(8,500,000)	-
Interest paid	(7,716,959)	(9,763,694)
Net Cash flow Used in Financing Activities Total (C)	**(16,216,959)**	**(9,763,694)**
Net Increase in Cash & Cash Equivalents (A + B + C)	**1,391,933**	**21,833,488**
Add: Cash and Cash Equivalents as at the beginning of the year	30,974,825	9,141,337
Cash and Cash Equivalents at year End	**32,366,758**	**30,974,825**

Cash & Bank balances comprises of :	₹	₹
Cash in hand	339,537	303,803
Bank Balance	21,989,819	22,064,152
Fixed deposit	10,037,402	8,606,870
	32,366,758	**30,974,825**

As per our report of even date attached

For MRC AND ASSOCIATES
Chartered Accountants
Firm Registration No.: 004005S

G. Chiranjeevulu
Partner
Membership No.: 215032

Place: Chennai
Date: 30.05.2022
UDIN: 22215032ANJMIW9993

For and on behalf of the Board of Directors

A.N. Radhakrishnan
Director
DIN :01508867

Gomathi Radhakrishnan
Managing Director
DIN: 02900460

Dr. V. Krishnamurthy
Chief Executive Officer
PAN: ABAPK5242M

R. Deenadayalu
Company Secretary
Membership No.: F3850

Dambaru Dhar Jena
Chief Financial Officer
PAN: AHOPD5875H

Place: Chennai
Date: 30.05.2022

CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LIMITED
(FORMERLY KNOWN AS DEVAKI HOSPITAL LIMITED)
CIN:L85110TN1990PLC019545
New No.70, Old No.149,Luz Church Road, Mylapore, Chennai-600 004

NOTE - 1 SIGNIFICANT ACCOUNTING POLICIES:-

A. Basis of Preparation of Financial Statements

These financial statements are prepared in accordance with Indian Accounting Standards ("Ind AS"). The Ind AS are prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules issued thereafter.

Accounting Policies have been consistently applied except where a newly- issued accounting standard is initially adopted or a revision to existing accounting standard requires a change in the accounting policy hitherto in use.

The preparation of financial Statements in conformity with Ind AS requires the Management to make estimates, Judgements and Assumptions. The application of accounting policies that require critical accounting estimates involving complex and subjective judgements and the use of assumptions in the financial statements have been disclosed in Note No. 1.1.

The financial statements are authorized for issue by the Company's Board of Directors on 30th May, 2022.

1.1 Accounting Estimates

A. Revenue Recognition

Rendering of Service

a. Healthcare Service:

Revenue primarily comprises fees charged for inpatient and outpatient hospital services. Services include charges for accommodation, theatre, medical professional services, equipment, radiology, laboratory and pharmaceutical goods used. IP Collections Accrued (Pending Bill) under "Other Current Assets" is recorded for the service where the patients are not discharged and invoice is not raised for the service.

Service revenue i.e. Inpatient / Outpatient Collections are presented net of related Consultants (Visiting Doctors)

b. Sale of Goods:

Pharmacy Sales are recognised when the risk and reward of ownership is passed to the customer. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government

B. Property, Plant and Equipment

Property, Plant and Equipment

Land and buildings held for use in providing the healthcare and related services, or for administrative purposes, are stated in the sheet at cost less accumulated depreciation and accumulated impairment losses. Freehold land is not depreciated.

Expenditure incurred after the property, plant and equipment have been put into operation, such as repairs and maintenance, are normally charged to the statements of profit and loss in the period in which the costs are incurred. Major inspection and overhaul expenditure is capitalized if the recognition criteria are met.

Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognized net within other income in statement of profit and loss.

Capital Work - in- Progress

Assets in the course of construction are capitalized in capital work in progress account. At the point when an asset is capable of operating in the manner intended by management, the cost of construction is transferred to the appropriate category of property, plant and equipment.

The cost of capital work-in-progress is presented separately in the balance sheet.

Leased Assets

Fixed assets acquired under Hire-Purchase agreements are capitalized to the extend of Principal Value, while finance charges are charged to revenue on accrual basis.

Borrowing Cost

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalized as part of cost of such assets. All other borrowing costs are charged to revenue, during the period in which they are incurred.

Depreciation

Assets in the course of development or construction and freehold land are not depreciated. Other property, plant and equipment are stated at cost less accumulated depreciation and any provision for impairment. Depreciation commences when the assets are ready for their intended use.

Depreciation on Property, Plant and Equipment is provided for on straight-line-basis, at the higher of the rates as specified in Schedule II to the Act or the rates derived based on the economic useful life of the asset as technically ascertained by the management at the end of the each financial year.

C. Inventories

Inventories of medical consumables, drugs and General stores are valued at cost or lower of net realizable value. Net Realizable Value represents the estimated selling price in the ordinary course of business less estimated costs of completion and estimated costs necessary to make the sale.

D. Provisions & Contingent Liabilities

Provisions are recognized when the company has a present obligation as a result of part event, for which it is probable that a cash outflow will be required and a reliable estimate can be made of the amount of the obligation. Contingent liabilities are not recognized but are disclosed at their estimate value in the notes to the Accounts. Contingent Assets are neither recognized nor disclosed in the Accounts.

E. Earnings per Share

The Company presents basic and diluted earnings per share ("EPS") data for its equity shares. Basic EPS is calculated by dividing the profit and loss attributable to equity shareholders of the Company by the weighted average number of equity shares outstanding during the period. Diluted EPS is determined by adjusting the profit and loss attributable to equity shareholders and the weighted average number of equity shares outstanding for the effects of all dilutive potential equity shares.

F. Cash and Cash Equivalents

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above.

G. Employee benefits – Defined Benefit Obligations

The cost of defined benefit plans are determined using actuarial valuations. The actuarial valuation involves making assumptions about discount rates, expected rates of return on assets, future salary increases, mortality rates and future pension increases.

H. Trade Receivables

Trade Receivables represent the amounts outstanding on sale of pharmaceutical products and hospital services which are considered as good by management.

Majority of the Company's transactions are earned in cash or cash equivalents. The trade receivables comprise mainly of receivables from Insurance Companies, customers. The entity's exposure to credit risk in relation to trade receivables is low.

I. Taxation

Provision for current tax is made in accordance with the Provisions of the Income Tax Act, 1961. Timing differences between accounting income and taxable income capable of being reversed in subsequent years are recognized as Deferred Tax.

J. Cash Flow Statement

Cash flows are reported using indirect method, whereby profit for the year is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information. The company considers all highly liquid investments that are readily convertible to known amounts of cash to be cash equivalents.

PROPERTY, PLANT AND EQUIPMENT

Note No.2

		GROSS BLOCK AT COST				Depreciation					NET BLOCK	
SL. NO.	PARTICULARS	AS AT 01.04.2021 (₹)	ADDITION FOR THE YEAR (₹)	DELETION DURING THE YEAR (₹)	AS AT 31.03.2022 (₹)	AS AT 01.04.2021 (₹)	Exceptional items	FOR THE YEAR (₹)	DELETION OR TRANSFER (₹)	AS AT 31.03.2022 (₹)	AS AT 31.03.2022 (₹)	AS AT 01.04.2021 (₹)
1	Land - Freehold	37,656,837		-	37,656,837	-		-	-	-	37,656,837	37,656,837
		(37,656,837)	-	-	(37,656,837)	-		-	-	-	(37,656,837)	(37,656,837)
2	Building - Freehold	53,803,508	-	-	53,803,508	16,020,705		1,259,427	-	17,280,132	36,523,376	37,782,803
		(53,803,508)	-	-	(53,803,508)	(14,761,278)		(1,259,427)	-	(16,020,705)	(37,782,803)	(39,042,230)
3	Improvement on Leased Building	19,568,098	-	-	19,568,098	19,568,102		-	-	19,568,102	-	-
		(19,568,098)	-	-	(19,568,098)	(17,724,149)		(1,843,953)	-	(19,568,102)	-	(1,843,949)
4	Plant & Equipment	140,208,097	19,572,510	247,154	159,533,453	101,214,936		7,047,150	-	108,262,086	51,271,367	38,993,161
		(139,354,757)	(853,340)	-	(140,208,097)	(95,011,292)		(6,203,644)	-	(101,214,936)	(38,993,161)	(44,343,465)
5	Electrical Fittings	18,207,007	3,357,046	-	21,564,053	12,085,361		1,287,167		13,372,528	8,191,525	6,121,645
		(17,994,286)	(212,721)	-	(18,207,007)	(10,879,465)		(1,205,896)	-	(12,085,361)	(6,121,645)	(7,114,821)
6	Furniture and Fittings	8,453,853	109,524	-	8,563,377	6,785,383		332,051	-	7,117,434	1,445,943	1,668,470
		(8,453,853)		-	(8,453,853)	(6,445,508)		(339,875)	-	(6,785,383)	(1,668,470)	(2,008,345)
7	Vehicle	5,962,993	-	-	5,962,993	2,677,144		681,805	-	3,358,949	2,604,044	3,285,849
		(5,914,741)	(61,806)	(13,554)	(5,962,993)	(1,998,184)		(680,483)	(1,523)	(2,677,144)	(3,285,849)	(3,916,557)
8	Ambulance	497,251	-	-	497,251	216,950		62,156	-	279,106	218,145	280,301
		(497,251)	-	-	(497,251)	(154,794)		(62,156)	-	(216,950)	(280,301)	(342,457)
9	Office Equipments	2,561,047	26,148	-	2,587,195	1,695,760		263,126	-	1,958,886	628,309	865,287
		(2,076,240)	(484,807)	-	(2,561,047)	(1,460,921)		(234,839)	-	(1,695,760)	(865,287)	(615,319)
10	Computer and Software	12,655,550	1,002,578	-	13,658,128	10,632,774		799,146	-	11,431,920	2,226,208	2,022,776
		(11,462,040)	(1,193,510)	-	(12,655,550)	(9,790,949)		(841,825)	-	(10,632,774)	(2,022,776)	(1,671,091)
Total		**299,574,241**	**24,067,806**	**247,154**	**323,394,893**	**170,897,115**	**-**	**11,732,028**	**-**	**182,629,143**	**140,765,759**	**128,677,134**
Previous Year		(296,781,611)	(2,806,184)	(13,554)	(299,574,241)	(158,226,540)	-	(12,672,098)	(1,523)	(170,897,115)	(128,677,134)	(138,555,074)

In the opinion of the management, taking in to consideration the future cash flows including estimated market values of the Assets especially Land and Building, no further adjustment for impairment in the carrying cost of Assets is considered necessary in the Accounts as at the year end.

NOTES TO FINANCIAL STATEMENTS

3 OTHER NON-CURRENT ASSETS

Particulars	March 31, 2022	March 31, 2021
	₹	₹
Security deposit	2,516,998	2,516,998
TOTAL	2,516,998	2,516,998

4 INVENTORIES [Valued at lower of cost and net realisable value, unless otherwise stated]

Particulars	March 31, 2022	March 31, 2021
Stock-in-trade (in respect of goods acquired for trading)	₹	₹
Medicines	3,336,911	5,054,560
General Stores	627,758	719,558
TOTAL	3,964,669	5,774,118

Method of Valuation of Inventories - See Note 1(c)of Significant Accounting Policies.

5 TRADE RECEIVABLES

Particulars	March 31, 2022	March 31, 2021
Considered good, Unsecured	₹	₹
Other Debts	9,205,240	7,885,550
TOTAL	9,205,240	7,885,550

[1] Trade Receivables ageing schedule

	Particulars	Outstanding for following periods from due date of payment					Total
		Less than 6 Months	6 Months - 1 Year	1 - 2 Years	2 - 3 Years	More than 3 Years	
		₹	₹	₹	₹	₹	₹
(i)	Undisputed Trade receivables - considered good	8,958,370	46,359	200,511	-	-	9,205,240
(ii)	Undisputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-
(iii)	Undisputed Trade Receivables - credit impaired	-	-	-	-	-	-
(iv)	Undisputed Trade Receivables - credit impaired	-	-	-	-	-	-
(v)	Disputed Trade Receivables- considered good	-	-	-	-	-	-
(vi)	Disputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-
(vii)	Disputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-
(viii)	Disputed Trade Receivables - credit impaired	-	-	-	-	-	-

6 CASH AND CASH EQUIVALENTS

Particulars	March 31, 2022	March 31, 2021
	₹	₹
Balance with Banks - In Current Accounts	21,989,819	22,064,152
Fixed Deposits with Banks ^	10,037,402	8,606,870
Cash on hand	339,537	303,803
TOTAL	32,366,758	30,974,825

^ *Represents deposits with Bank with original maturity of less than 12 months.*

7 OTHER CURRENT ASSETS

Particulars	March 31, 2022	March 31, 2021
	₹	₹
Prepaid Expenses	1,952,868	2,063,706
Advance to Employees	1,499,375	990,566
Advance to Suppliers	782,500	1,425,071
Interest Receivable	299,208	-
Advances Recoverable in cash or in kind	-	27,365
Income Tax Advance / TDS & Input tax credit	18,887,653	8,860,169
Accrued Income- IP collection	1,631,055	1,619,615
TOTAL	25,052,659	14,986,492

8 EQUITY SHARE CAPITAL

Particulars	**As at March 31, 2022**		**As at March 31, 2021**	
	No. of Shares	**Amount (₹)**	**No. of Shares**	**Amount (₹)**
Authorised Shares				
Equity Shares of ? 10 each	15,000,000	150,000,000	15,000,000	150,000,000
Issued Subscribed and Paid up capital				
Equity Shares of ? 10 each fully paid-up	7,468,920	74,689,200	7,468,920	74,689,200
a) Reconciliation of the Shares Outstanding at the beginning and at the end of the year				
Outstanding at the beginning of the Year	7,468,920	74,689,200	7,468,920	74,689,200
Shares Issued during the Year	-	-	-	-
Outstanding at the end of the year	7,468,920	74,689,200	7,468,920	74,689,200
(b) List of shareholders holding more than 5% of Paidup Equity Share capital	**No. of Shares**	**% Holding**	**No. of Shares**	**% Holding**
A. N Radhakrishnan	3,757,166	50.30%	3,743,947	50.12%
Gomathy R	408,892	5.47%	408,892	5.47%

8.1 SHARE HOLDING OF PROMOTORS

Shares held by promoters at March 31, 2022

S. No	Promotor Name	As at March 31, 2022		As at March 31, 2021		% Change during the year
		No. of Shares	% of Total Shares	No. of Shares	% of Total Shares	
1	A. N Radhakrishnan	3,757,166	50.30%	3,743,947	50.12%	0.00%
2	Gomathy R	408,892	5.47%	408,892	5.47%	0.00%

Shares held by promoters at March 31, 2021

S. No	Promotor Name	As at March 31, 2021		As at March 31, 2020		% Change during the year
		No. of Shares	% of Total Shares	No. of Shares	% of Total Shares	
1	A. N Radhakrishnan	3,743,947	50.12%	3,743,947	50.12%	0.00%
2	Gomathy R	408,892	5.47%	408,892	5.47%	0.00%

8.2 Terms/Rights attached to equity shares

The Company has only one class of equity shares having par value of ` 10/ each. Each holder of the equity share is entitled to one vote per share. In the event of liquidation of the Company, the equity shareholders will be entitled to receive the remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

8.3 The Net worth of the company is fully eroded and as on Balance sheet date, Net worth is negative ₹ 77,68,300/ . The current liabilities as at the year end has exceeded the Current Assets by ₹ 3,67,00,221/-. However, the management is of the opinion that considering the estimated future cash flows, the company will be able to continue as a going concern.

9 B. Other Equity

Particulars	Capital Reserve	Share Premium Reserve	Retained Earnings	Total
	₹	₹	₹	₹
Balance As at March 31, 2020	273,200	5,710,830	(116,279,393)	(110,295,363)
Additions during the year				
Profit / (Loss) for the year 2020-21	-	-	(12,497,186)	(12,497,186)
Other Comprehensive Income	-	-	400,548	400,548
Balance As at March 31, 2021	**273,200**	**5,710,830**	**(128,376,031)**	**(122,392,000)**
Additions during the year				
Profit / (Loss) for the year 2021-22	-	-	39,758,699	39,758,699
Other Comprehensive Income	-	-	175,804	175,804
Balance As at March 31, 2022	**273,200**	**5,710,830**	**(88,441,528)**	**(82,457,497)**

10 NON - CURRENT BORROWINGS

Particulars	March 31, 2022	March 31, 2021
Loans from related parties [SECURED]	₹	₹
Loan from Director [See Note 10.1]	106,263,826	114,763,826
TOTAL	**106,263,826**	**114,763,826**

10.1 **Details of security**

Loan from director is secured by registered equitable mortgage of title deed of Building bearing Door No:149, Luz Church Road, Mylapore, Chennai-600 004

11 NON - CURRENT PROVISIONS

Particulars	March 31, 2022	March 31, 2021
Provision for employee benefits [Refer Note No.22]	₹	₹
Gratuity	6,972,129	5,639,531
Compensated Absences	1,114,881	1,130,422
TOTAL	**8,087,010**	**6,769,953**

12 TRADE PAYABLES - Total Outstanding Dues of creditors other than Micro Enterprises and Small Enterprises

Particulars	March 31, 2022	March 31, 2021
	₹	₹
For Goods Supplied	3,383,043	2,755,416
For Services Received	16,800,985	12,284,451
TOTAL	**20,184,028**	**15,039,867**

TRADE PAYABLES AGING SCHEDULE

	Particulars	Outstanding for following periods from due date of payment				Total
		Less Than 1 Year	1 - 2 Years	2 - 3 Years	More than 3 Years	
		₹	₹	₹	₹	₹
(i)	MSME					
(ii)	Others	20,184,028				
(iii)	Disputed dues — MSME					
(iv)	Disputed dues - Others					

13 OTHER CURRENT LIABILITIES:

Particulars	March 31, 2022	March 31, 2021
	₹	₹
Advance from customers	190,240	361,552
Statutory Dues	3,764,682	3,000,124
Interest Accrued but not due on Borrowings [1]	82,077,121	98,289,483
TOTAL	**86,032,043**	**101,651,159**

[1] The Terms of payment of interest on loan from Director and related concern is not stipulated and hence, in the opinion of the management, the said interest is considered as accrued but not Due. Rate of interest on the above loans are accounted at 7% per annum.

14 SHORT TERM PROVISIONS

Particulars	March 31, 2022	March 31, 2021
Provision for employee benefits [Refer Note No.22]	₹	₹
Gratuity	592,709	1,124,789
Compensated Absences	480,764	366,283
TOTAL	**1,073,473**	**1,491,072**

15 REVENUE FROM OPERATIONS

Particulars	March 31, 2022	March 31, 2021
	₹	₹
Sale of Products		
Pharmacy Sales	96,733,492	68,152,564
Sale of Services		
Inpatient / Outpatient Collections [1]	215,851,628	125,475,900
Hostel Fees Collection	499,300	466,910
Other Operating Revenue		
Rent Received	778,608	723,359
TOTAL	**313,863,028**	**194,818,733**

[1] *Hospital Collections are shown net of payments to Consultants (visiting doctors)*

16 OTHER INCOME

Particulars	March 31, 2022	March 31, 2021
	₹	₹
Interest Income	771,118	1,398,346
Other non operating Income	3,119,564	3,792,240
TOTAL	**3,890,682**	**5,190,586**

17 CHANGES IN INVENTORIES OF STOCK - IN - TRADE

Particulars	March 31, 2022	March 31, 2021
	₹	₹
Inventory at the end of the period	3,964,669	5,774,118
Inventory at the beginning of the period	5,774,118	6,839,878
(Increase)/ Decrease in inventories	**1,809,449**	**1,065,760**

18 EMPLOYEE BENEFITS EXPENSES

Particulars	March 31, 2022	March 31, 2021
	₹	₹
Salary,Wages and Exgratia	74,044,098	62,155,050
Contribution to Provident Fund	3,970,528	3,006,398
Contribution to ESI	1,122,172	845,170
E L Encashment	762,385	445,691
Gratuity	1,592,599	1,511,935
Staff Welfare	1,223,719	1,266,499
TOTAL	**82,715,501**	**69,230,743**

19 FINANCE COSTS

Particulars	March 31, 2022	March 31, 2021
	₹	₹
Bank Charges	2,132,241	1,626,264
Interest Expenses	7,716,959	9,763,694
TOTAL	**9,849,200**	**11,389,958**

20 OTHER EXPENSES

Particulars	March 31, 2022	March 31, 2021
	₹	₹
Power & Fuel	6,207,649	5,101,860
Lab Chemicals & Consumables	26,415,198	21,530,176
Rent	7,800,000	7,800,000
Repairs & Maintenance		
- Plant	4,884,364	3,786,471
- Building	8,372,864	495,280
- Others	5,673,622	2,957,517
Consultancy Fees	19,761,566	9,161,088
Professional Fees	1,333,604	1,364,690
Rates & Taxes	1,109,833	1,369,841
Advertisement expenses	332,298	228,495
Insurance expenses	420,884	415,008
House Keeping Charges	3,846,338	3,695,082
Audit Fees (See Note 20.1)	485,200	449,800
Discount	5,259,172	3,302,294
Service Charges	4,200,111	3,626,817
Printing & Stationery	2,021,117	1,471,164
Travelling Expenses	2,179,481	824,347
Telephone	819,524	697,031
Bad Debts Written off	-	1,117,682
Ethics Committee Expenses	2,109,132	2,122,204
Miscelleous Expenses	853,844	988,369
TOTAL	**104,085,799**	**72,505,216**

20.1 PAYMENTS TO AUDITORS

Particulars	March 31, 2022	March 31, 2021
	₹	₹
Statutory Audit fee	230,000	230,000
Other services		
-Tax audit	60,000	60,000
-Others	30,000	30,000
Internal Audit Fee	165,200	129,800
TOTAL	**485,200**	**449,800**

21 CALCULATION OF EARNINGS PER SHARE

Particulars	March 31, 2022	March 31, 2021
	₹	₹
Net profit/(Loss) as per Profit &Loss Statement	39,758,699	(12,497,186)
No. of Shares Outstanding (Face Value ₹ 10 per share)	7,468,920	7,468,920
TOTAL	**5.32**	**(1.67)**

22 EMPLOYEE BENEFITS

a. Defined Contribution Plans

During the year the following amounts have been recognised in the Statement of profit and loss on account of defined contribution plans:

Particulars	2021-22 ₹	2020-21 ₹
Employers contribution to Provident Fund	3,970,528	3,006,398

b. Defined Benefit Plans - Gratuity: Funded Obligation

i. Principal Actuarial Valuation	2021-22	2020-21
Discount Rate (per annum)	6.96%	6.82%
Expected rate of return on plan assets	0.00%	0.00%
Annual increase in salary costs [1]	5.83%	5.83%
Attrition rate	5% - to - 1%	5% - to - 1%
Mortality Table	IALM (2012-14) Ult	IALM (2012-14) Ult

[1] The estimates of future salary increase, considered in actuarial valuation, take account of inflation, seniority, promotion, and other relevant factors, such as supply and demand in the employment market.

	Leave Benfit		Gratuity	
ii. Amounts to be recognized in the Balance Sheet	2021-22 ₹	2020-21 ₹	2021-22 ₹	2020-21 ₹
Present value of funded obligations	1,496,705	1,595,645	7,564,838	6,764,320
Fair value of plan assets	-	-	-	-
Net Obligations	1,496,705	1,595,645	7,564,838	6,764,320
Net defined benefit Liability / (Asset) recognized in Balance sheet	1,496,705	1,595,645	7,564,838	6,764,320

	Leave Benfit		Gratuity	
iii. Expenses recognized in the Income Statement	2021-22 ₹	2020-21 ₹	2021-22 ₹	2020-21 ₹
Service Cost	480,764	366,283	1,131,272	1,124,789
Net Interest Cost	102,075	79,408	461,327	387,146
Net Actuarial (gain) / Loss	179,546	-	-	-
Total expenses recognized in the statement of profit and loss for the year	762,385	445,691	1,592,599	1,511,935

Other Comprehensive income (Re-measurements of net benefit liability (Assets))

	Leave Benfit		Gratuity	
iv. Actuarial (gains) / losses arising from	2021-22 ₹	2020-21 ₹	2021-22 ₹	2020-21 ₹
Opening amount recognized in OCI outside profit and loss account	N/A	-	-	-
Actuarial gain / (Loss) on liabilities	N/A	78,355	175,804	322,194
Actuarial gain / (Loss) on Assets	N/A	-	-	-
Closing of amount recognized in OCI outise profit and loss account	N/A	78,355	175,804	322,194

v. Reconciliation of present value of obligation	Leave Benfit		Gratuity	
	2021-22 ₹	2020-21 ₹	2021-22 ₹	2020-21 ₹
Opening defined benefit obligation	1,496,705	1,273,305	6,764,320	6,139,383
Service Cost	480,764	366,283	1,131,272	1,124,789
Interest Cost	102,075	79,408	461,327	387,146
Benefits Paid	(663,445)	(143,936)	(616,277)	(564,805)
Actuarial (gains)/ losses on Total Liabilities	179,546	(78,355)	(175,804)	(322,194)
- due to change in financial assumptions	(21,077)	1,533	(86,998)	4,353
- due to change in demographic assumptions	-	-	-	-
- due to change in experience changes'	200,623	(79,888)	(88,806)	(326,547)
Closing defined benefit obligation	**1,595,645**	**1,496,705**	**7,564,838**	**6,764,320**

c. Present Value of Obiligation at the end of the year

Particulars	Leave Benfit		Gratuity	
	2021-22 ₹	2020-21 ₹	2021-22 ₹	2020-21 ₹
Current liability	131,064	82,983	592,709	1,124,789
Non Current Liability	1,464,581	1,413,722	6,972,129	5,639,531
Total Liabilities	1,595,645	1,496,705	7,564,838	6,764,320

23 RATIO ANALYSIS

Ratio	Numerator / Denomirator	2021-22	2020-21
(a) Current Ratio	Current Assets / Current Liabilities	0.66	0.50
(b) Debt-Equity Ratio	Total Liabilities / Total Shareholder's Equity	-28.53	-5.03
(c) Debt Service Coverage Ratio	Net Operating Income / Total Debt Service	3.65	1.02
(d) Return on Equity Ratio	Profit after Tax / Total Shareholder's Equity	-5.12	0.26
(e) Inventory turnover ratio	Cost of Goods Sold / Average Inventory	14.30	7.41
(f) Trade Receivables turnover ratio	Net Credit Sales / Average Trade Receivable	34.01	24.61
(g) Trade payables turnover ratio	Net Credit Purchases / Average Trade Payable	13.77	14.13
(h) Net capital turnover ratio	Total Income / Total Shareholder's Equity	-40.90	-4.19
(i) Net profit ratio	Net profit / Net Sales	0.13	-0.06
(j) Return on Capital employed	EBIT / Capital Employed	0.45	-0.04
(k) Return on investment	Net profit / Total Assets X 100	0.19	-0.07

Notes		₹	₹
1. Current Assets		70,589,326	59,620,985
2. Current Liabilities		107,289,544	118,182,098
3. Total liabilities		221,640,380	239,715,877
4. Total Shares Holder's Equity		-7,768,297	-47,702,800
5. Net Operating Income		59,207,686	9,938,606
6. Total Debt Service		16,216,960	9,763,694
7. Profit after Tax		39,758,699	-12,497,186
8. Cost of Goods Sold		69,612,483	46,708,491
9. Average Inventory		4,869,394	6,306,998
10. Net Credit Sales		313,084,420	194,095,374
11. Average Trade Receivables		9,205,240	7,885,550
12. Net Credit Purchase		277,995,011	212,506,505
13. Average Trade Payables		20,184,028	15,039,867
14. Total Income		317,753,710	200,009,319
15. Net Profit		39,758,699	-12,497,186
16. Net Sales		317,753,710	200,009,319
17. EBIT		47,475,658	-2,733,492
18. Capital Exployed		106,582,539	73,830,979
19. Total Assets		213,872,083	192,013,077

24 In the opinion of the Directors, Current Assets, Loans and Advances have the value at which they are stated in the Balance Sheet, if realized in the ordinary course of business.

25 Balances of Sundry Debtors & Creditors, Loans and Advances are subject to confirmation / reconciliation.

26 Related Party Disclosures

The particulars that is required to be disclosed in terms of Ind AS- 24 Related Party Disclosures issued by the Institute of Chartered Accountants of India are furnished below:

(a). List of Related Parties:-

(i) Subsidiary Companies: NIL

(ii) Associates : NIL

(iii) Key Management Personnel

Mr. A.N Radhakrishnan	Director
Mrs. R. Gomathi	Managing Director
Dr. V. Krishnamurthy	Chief Executive Officer
Mr. Dambaru Dhar Jena	Chief Financial Officer
Mr. R. Deenadayalu	Company Secretary & Compliance Officer
Mr. B. Ramachandran	Independent Director - till 09.06.2021
Mr. N Rajkumar	Independent Director - till 20.05.2021 and from 09.06.2021
Mr. K. Meyyanathan	Independent Director - from 20.05.2021

(iii) Relatives of Key Management Personnel

Mrs.Gomathi	Wife of Sri. A.N Radhakrishnan
Mr. R. Navin Raakesh	Son of A.N Radhakrishnan
Dr. R. Gokul krishnan	Son of A.N Radhakrishnan
Mrs. R. Jayanthi	Daughter of A.N Radhakrishnan
Dr. M. Shobana	Daughter-in-law of A.N. Radhakrishnan
Dr. V. Abinaya	Daughter-in-law of A.N. Radhakrishnan

(iv) Enterprises over which key management personnel or their relatives are able to exercise significant influence

1. Meenakshi Ammal Trust
2. Meenakshi College of Engineering
3. Sri Muthukumaran Educational Trust
4. Sri Muthukumaran Institute of Technology
5. Arulmigu Meenakshi Amman Higher Secondary School
6. Meenakshi Medical College and Research Institute
7. Meenakshi Universtiy
8. Meenakshi Ammal Arts and Science College
9. Meenakshi Ammal Dental College
10. Meenakshi College of Physiotherapy
11. Arulmigu Meenakshi Amman College of Education
12. Gokul Hospitals Services Private Limited
13. DINAETHAL- Tamil Newspaper
14. Meenakshi Networks Pvt Ltd
15. RMG Nidhi Limited

(One of the Director is the Managing Trustee / Director in the above trusts /Companies)

(b). Transaction With Related Parties:- **[In ₹]**

Particulars	Key Management Personnel	Relative of key Management Personnel	Enterprises
Rendering of services	1,639,225	-	-
Receiving of services	900,000	-	-
Leasing/Hire purchase Arrangements	300,000		6,300,000
Finance (Including Interest on Loan)	7,709,481	-	-
Balance outstanding as on 31.03.2022	188,340,750	-	-

27 The Company's Operation comprises of only on segment - hospital Activities. There is no other business or geographical segments required under IND AS-108 "Operating Segment"

28 Taxes

a) Current Tax

No provision for current tax is required to be made in the books of accounts for the year as per the management`s Computation due to the losses incurred by the company in the prior years.

b) Deferred Tax

The company has not recognized Deferred Tax Asset (net) in the accounts as a matter of prudence.

29 Estimated amount of contracts remaining to be executed on capital account is Nil, P.Y. Nil

30 Changes in Equity reported in accordance with previous GAAP to its equity in accordance with Ind AS : Nil

31 Figures in brackets unless otherwise stated, represent figures of the previous year. Previous year's figures have been regrouped / recast wherever necessary to confirm to the current year's lay out.

As per our report of even date attached

For MRC AND ASSOCIATES
Chartered Accountants
Firm Registration No.: 004005S

G. Chiranjeevulu
Partner
Membership No.: 215032

Place: Chennai
Date: 30.05.2022
UDIN: 22215032ANJMIW9993

For and on behalf of the Board of Directors

A.N. Radhakrishnan
Director
DIN :01508867

Gomathi Radhakrishnan
Managing Director
DIN: 02900460

Dr. V. Krishnamurthy
Chief Executive Officer
PAN: ABAPK5242M

R. Deenadayalu
Company Secretary
Membership No.: F3850

Dambaru Dhar Jena
Chief Financial Officer
PAN: AHOPD5875H

Place:Chennai
Date: 30.05.2022

A Historical Perspective

(₹ in Lakhs)

	2021-22	2020-21	2019-20	2018-19	2017-18
PROFIT & LOSS					
Gross Income	3177.54	2000.09	2649.37	2285.73	2368.93
Profit/ (Loss) before Depreciation & Financial Expenses	613.40	115.64	317.95	260.74	403.05
Financial Expenses	98.49	113.90	138.68	136.21	138.79
Depreciation	117.32	126.72	124.37	119.67	114.53
Profit/(Loss) before Exceptional Items	397.59	(124.98)	54.91	4.86	149.73
Exceptional Items	0	0	0	0	0
Profit/(Loss) after Exceptional Items	397.59	(124.98)	54.91	4.86	149.73
Tax Expenses					
a. Current Tax	0	0	0	0	0
b. Deferred Tax Liability	0	0	0	0	0
c. Tax for Earlier Year	0	0	0	0	0
Other Comprehensive Income	1.76	4.01	2.07	(0.62)	6.82
Total Income/(Loss) for the Year	399.35	(120.97)	56.98	4.24	156.55
Earning Per Shares (EPS) in ₹	5.32	(1.67)	0.74	0.07	2.00
LIABILITIES & ASSETS					
LIABILITIES					
Equity					
Equity Share Capital	746.89	746.89	746.89	746.89	746.89
Reserve & Surplus	(824.58)	(1223.92)	(1102.95)	(1159.93)	(1164.18)
Total (a)	(77.69)	(477.03)	(356.06)	(413.04)	(417.29)
Non Current Liabilities					
Loan term Borrowings	1062.64	1147.64	1147.64	1147.64	1147.64
Long term Provisions	80.87	67.70	57.67	50.42	54.30
Total (b)	1143.51	1215.34	1205.31	1198.06	1201.94
CURRENT LIABILITIES					
Short Term Borrowings	0	0	0	73.54	78.16
Trade Payables	201.84	150.40	114.27	123.79	140.89
Other Current Liabilities	860.32	1016.51	964.99	927.08	925.96
Short term Provisions	10.74	14.91	16.45	9.11	5.15
Total (C)	1072.90	1181.82	1095.71	1133.52	1150.16
Total Liabilities (a+b+c)	2138.72	1920.13	1944.96	1918.54	1934.81
ASSETS					
NON CURRENT ASSETS					
Fixed Assets					
i) Tangible Assets	1407.66	1286.77	1385.55	1407.11	1452.85
ii) Capital Work in Progress	0	11.97	11.97	11.97	1.98
Other Non Current Assets	25.17	25.17	25.07	24.49	24.49
Total (d)	1432.83	1323.91	1422.59	1443.57	1479.32
CURRENT ASSETS					
Inventories	39.65	57.74	68.40	63.30	80.51
Trade Receivables	92.05	78.86	105.84	82.82	76.66
Cash & Bank Balances	323.67	309.75	91.41	99.23	89.41
Short term Loans & Advances	0	133.67	249.22	219.78	193.07
Other Current Assets	250.52	16.20	7.50	9.84	15.84
Total (e)	705.89	596.22	522.37	474.97	455.49
TOTAL ASSETS (d+e)	2138.72	1920.13	1944.96	1918.54	1934.81